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I. Introduction 
There is a large number of patients waiting for cells, tissues and organs for 
transplantation worldwide, but the available human donors cannot fill this need. 
Xenotransplantation might be a good solution to close this gap. Pigs seem to be the 
best source as potential donor animals because of their physiological similarity with 
humans, ethical issues, easy genetic manipulation and high reproduction rate. Recent 
progress in xenotransplantation preclinical studies suggest that immunological hurdles 
and species-specific incompatibilities are manageable. At this step it becomes 
necessary to elucidate safety issue before going to the clinical studies on human 
recipients. Transmission of pathogens like bacteria, fungi, protozoa and many viruses 
can be controlled or eliminated with different approaches like designated pathogen-
free (DPF) breeding conditions, vaccines, drugs or early weaning. These strategies, 
however, are not able to eliminate porcine endogenous retroviruses (PERV), which are 
permanently integrated in the porcine genome and are inherited according to 
Mendelian rules. There are three relevant subtypes of PERV. Among them A and B 
are able to infect human cells in vitro, whereas subtype C alone infects only porcine 
cells. However, when PERV C recombined with PERV A, a highly infectious PERV 
A/C was capable to infect also human cells. Therefore, it is highly recommended for 
xenotransplantation to use donor pigs that do not contain PERV C in their genome. 
The objective of this thesis was to delete the infectious potential of PERV C from 
donor pigs for xenotransplantation through two different approaches, namely selective 
breeding and excision of PERV C by CRISPR/Cas technology. Both strategies needed 
at first the detection, localization and characterization of the provirus loci within the 
genome. For selective breeding all animals of our herd were tested for PERV C loci to 
learn more about the PERV C load and to design breeding strategies for provirus 
eradication. CRISPR/Cas technology was used to excise PERV C from the genome of 
a multimodified pig line and to generate single cell clones, which can be then used for 
somatic cell nuclear transfer (SCNT) to generate PERV C free animals.
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II. Review of Literature
1. Xenotransplantation 
The term transplantation designates the replacement of cells, tissues and organs 
between individuals of the same species, allotransplantation, or between different 
species, xenotransplantation. Allotransplantation is the preferred solution for patients 
who are waiting for an organ graft, but the number of patients is much higher than the 
number of potential organ donors (PUGA YUNG et al., 2017). For example, more than 
100.000 patients only in the United States are currently waiting for kidney transplants 
and a presumably larger number of patients around the world are on waiting lists 
(WIJKSTROM et al., 2017). Likewise, there is a big shortfall of cells or tissues like 
corneal and pancreatic islet for millions of blind or diabetic patients (EKSER et al., 
2015). Xenotransplantation might fill this gap. The practice of xenotransplantation 
started already in the 19th century using skin, cornea, cells, slice of tissue from different 
animals into humans; after establishing techniques for blood vessel anastomosis whole 
organ xenotransplantation became an option as well (COOPER et al., 2015). Clinical 
attempts of renal xenotransplantation were performed from the beginning of the 20th 
century but due to inadequate knowledge of rejection mechanisms and insufficient 
immunosuppression the patients died within a very short period of time (SAMSTEIN 
& PLATT, 2001). 60 years later the survival of a patient receiving a kidney transplant 
from chimpanzee was prolonged till 9 months when using strong immunosuppressant 
drugs (REEMTSMA et al., 1964). Although primates are the closest relatives to 
humans, they are not seen optimal xenograft donors because of the high risk of 
infectious agent transmission, ethical reasons, size of organs, expensive breeding and 
long reproduction time (COOPER et al., 2002). Instead, the pig is seen nowadays as 
the preferred donor species because of the high similarities to humans in physiological, 
anatomical and immunological terms (SACHS, 1994). 
 
 
 
 
II. Review of Literature 3 
 
 
 
2. Xenograft rejection: Hurdles and approaches to overcome them 
by genetic modification or systemic drugs  
When transplanted into a primate a pig organ becomes a target of different 
immunological responses that cannot be sufficiently controlled with 
immunosuppressant therapy alone (COOPER et al., 2016). However, the option of 
genetic modification offers a way for overcoming immunological rejection of 
xenografts either by deleting unwanted genes or adding desired genetic functions 
(SACHS & GALLI, 2009; COOPER, 2015).  
2.1.  Hyperacute rejection 
The first reason of the xenograft loss is the hyperacute rejection (HAR), which 
normally happens immediately after transplantation due to the interaction of 
preformed anti-pig-antibodies with targets on the graft cells. The main responsible 
epitope for HAR is the galactosyl α-(1,3)-galactosyl β-1,4-N-acetyl glucosaminyl ( α-
Gal), a carbohydrate that is present in high quantity on pig cells (TANEMURA et al., 
2000) and other mammals species, while it is lacking in humans, apes and Old World 
monkeys (GALILI et al., 1988). The production of antibodies against α-Gal epitopes 
in humans is induced by bacteria in the intestinal flora (GALILI et al., 1984). These 
antibodies bind α-Gal epitopes on the vascular endothelial cells of the xenograft and 
trigger the activation of complement system and coagulation (YANG & SYKES, 
2007). Eventually this process results in vascular thrombosis, necrosis and finally 
xenograft rejection (PIERSON, 2009). To overcome or to reduce HAR, different 
approaches were examined, but the most efficient one proved the disruption of 
GGTA1, the gene which is responsible for the synthesis of α-Gal on the porcine 
endothelial cells surfaces. After the knockout of GGTA1 on one allele (DAI et al., 
2002; LAI et al., 2002), pigs were produced that did not express α-Gal after 
homozygous deletion of GGTA1 (PHELPS et al., 2003). Further GGTA1 knock out 
(GTKO) pigs were produced with different methods (WATT et al., 2006; KLYMIUK 
et al., 2010; HAUSCHILD et al., 2011). Since GTKO effectively prevented hyperacute 
rejection of porcine xenografts and significantly prolonged their survival in non-
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human primates this approach became an absolute prerequisite in xenotransplantation 
practice (KUWAKI et al., 2005; SHIMIZU et al., 2008). Other glycosylic 
xenoantigens induce binding of human antibodies on the porcine cell surface in 
addition to α-Gal (PADLER-KARAVANI & VARKI, 2011). Very important among 
them is N-glycolylneuraminic acid (Neu5Gc), which is not produced in humans due 
to the inactive CMAH gene (TANGVORANUNTAKUL et al., 2003), and an 
oligosaccharide synthesized by β-1, 4-N-acetyl-galactosaminyl transferase 2 
(B4GALNT2), which is homologous to the enzyme that synthesizes the SDa blood 
group antigen in humans (BYRNE et al., 2018). Tests for antibody-binding with cells 
from pigs missing both GGTA1 and CMAH genes shown a decreased bound of IgM 
compared to GTKO pig cells (LUTZ et al., 2013). On the other hand, human 
embryonic kidney (HEK-B4T) cells expressing B4GALNT2 when sensitized with 
primate serum after cardiac xenotransplantation demonstrated a 20-fold increased 
antibody binding and complement-mediated cell lysis (BYRNE et al., 2014).  For both 
genes, however, it is unclear if their deletion is an ultimate necessity for 
xenotransplantation.
2.2. Vascular rejection 
As shown, humoral rejection of xenograft by preformed antibodies can be attenuated, 
but the release of induced antibodies can still activate xenograft endothelium and  
result in complement mediated acute vascular rejection (COWAN et al., 2009). The 
complement system is a set of proteins expressed on the surface of cells and controlled 
by complement regulatory proteins (CRPs) with the function to protect from 
complement mediated injury (SAMSTEIN & PLATT, 2001). Porcine cells have 
similar complement regulatory proteins (CRPs) as humans, but their endogenous 
expression is not able to inhibit  human complement (COOPER et al., 2016). To 
overcome this obstacle, it is tempting to generate genetically modified pigs that 
express human CRPs. Different of such attempts on the most relevant CRPs have been 
documented.   
Human decay-accelerating factor (hDAF or CD55) is expressed on the surface of 
vascular endothelial cells and is able to inhibit complement activation (KIM et al., 
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2012). Moreover, this regulatory protein is a ligand of CD97, which is expressed on 
granulocytes and monocytes and can inhibit natural killer (NK) cells and lymphocyte 
T cells (DHO et al., 2018). Therefore, different groups generated pig lines that express 
CD55 (LANGFORD et al., 1994; LAVITRANO et al., 2002) and others established 
double transgenic pigs with lack of GGTA1 gene in addition to CD55 expression 
(MCGREGOR et al., 2012; AZIMZADEH et al., 2015).  
Another important CRP is the human membrane cofactor protein called CD46 that is 
responsible for the inactivation of C3b and C4b (SEYA et al., 1999). CD46 expression 
prolonged survival of baboons who received CD46 transgenic porcine hearts for up to 
23 days, while wild-type grafts were rejected within 90 minutes (DIAMOND et al., 
2001). A kidney from a CD46 transgenic pig transplanted without immunosuppression 
demonstrated xenograft protection from complement mediated lysis (LOVELAND et 
al., 2004). A transgenic pig line that expresses a combination of CD46 and CD55 plus 
a third complement regulatory protein, CD59, which inhibits formation of the 
complement membrane attack complex, demonstrated that the expression of more 
CRPs results in a better xenograft protection against human complement mediated 
injury (FODOR et al., 1994; NIEMANN et al., 2001; ZHOU et al., 2005).  
To further limit activation of vascular  endothelial cells, damage and acute vascular 
rejection of xenograft, pigs were established that expressed anti apoptotic and anti-
inflammatory molecules like heme oxygenase-1 (HO-1) and tumor necrosis factor 
alpha-induced protein (A20) (OROPEZA et al., 2009; PETERSEN et al., 2011). HO-
1 reduces formation of pro-inflammatory factors, NK cells activity and its 
overexpression diminishes IgM deposition and thrombus formation (YEOM et al., 
2012). HO-1 and A20 were also used in addition to CRPs to generate multiple 
transgenic pigs (AHRENS et al., 2015a; FISCHER et al., 2016). 
2.3.  Cellular rejection 
Even if antibody-mediated rejection is sufficiently controlled, xenografts become 
object of delayed xenograft cellular rejection mediated by T lymphocytes, 
macrophages and natural killer cells (cellular rejection) (SCHNEIDER & SEEBACH, 
2008). Again, genetic modifications of pigs might overcome these hurdles. T cell 
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mediated response against the vascular endothelium of the transplanted organ is 
triggered either directly by pig SLA class I and II proteins or indirectly when porcine 
peptides are presented by the recipient’s major histocompatibility complex (MHC) 
class II (HIGGINBOTHAM et al., 2015). Transgenic pigs were produced that express 
a human dominant negative mutant MHC class II trans activator gene (CIITA-DN) in 
order to down regulate the expression of SLA class II on the porcine cells (IWASE et 
al., 2015). This transgene decreased significantly the CD4+  T-cell response against 
aortic endothelial cells from CIITA-DN pigs (pAECs) (HARA et al., 2013). 
Alternatively, cellular rejection might be also avoided by preventing T-cells activation 
through the expression of cytotoxic T lymphocyte-associated antigen (CTLA4) fused 
to the Fc of human IgG (CTLA4-Ig) (PHELPS et al., 2009). CTLA4-Ig inhibits the 
interaction between  T-cells  B7 receptor and CD80 and CD86 ligands during antigen 
presentation (KOSHIKA et al., 2011; ZHANG et al., 2015). As CTLA4-Ig does not 
fully prevent T-cells activation, a more potent variant of this protein (LEA29Y) was 
developed by the exchange of two amino acids (LARSEN et al., 2005). Specific 
expression of LEA29Y in pancreatic β-cells (INSLEA29Y) resulted in prolonged islet 
xenograft function (KLYMIUK et al., 2012; BUERCK et al., 2017).  
Another promising target is tumor necrosis factor-related apoptosis-inducing ligand 
(TRAIL). This ligand interacts with different receptors, induces apoptosis in most 
transformed cells, downregulates immune responses via cell cycle  inhibition  of 
lymphocytes  (SONG et al., 2000) and of plasma cells after the end of antibodies 
secretion (URSINI-SIEGEL et al., 2002).  In vitro and in vivo studies demonstrated 
the capacity of TRAIL to induce apoptosis in Jurkat and Hut cells (immortalized T 
lymphocytes) (KLOSE et al., 2005) and to inhibit human T lymphocytes cell cycle 
when exposed to dendritic cells obtained from pigs that express TRAIL on a GGTA1 
KO/CD46 background (KEMTER et al., 2012). Moreover, when expressed on NK 
cells TRAIL eliminates activated  CD4+ T lymphocytes and neutrophils (RENSHAW 
et al., 2003; SCHUSTER et al., 2014).  
NK cells distinguish self from non-self by recognizing MHC class I through inhibiting 
receptors (RAULET et al., 2001; CARRILLO-BUSTAMANTE et al., 2016). One of 
them is CD94/NKG2, which interacts specifically with the human leukocyte antigen 
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(HLA-E) (LEE et al., 1998). NK cells were demonstrated to infiltrate and destroy 
porcine tissues (INVERARDI et al., 1992; KHALFOUN et al., 2000) and to activate 
vascular endothelial cells (GOODMAN et al., 1996; VON ALBERTINI et al., 1998).  
Thus, HLA-E was expressed on pig endothelial cells in order to decrease NK cells 
response (WEISS et al., 2009). In vitro experiments  and different ex vivo studies with 
pigs expressing HLA-E in different constellations with other transgenes confirmed the 
protective effect against NK cell-mediated cell lysis or xenograft rejection (LAIRD et 
al., 2017; ABICHT et al., 2018; PUGA YUNG et al., 2018). 
2.4.  Coagulation 
In addition to triggering complement-mediated rejection, induced xenoantibodies can 
also activate endothelial cells to express tissue factor (TF), thus switching the 
anticoagulant state into a procoagulant one (LIN et al., 2009). TF binds coagulation 
factor VII, which auto-cleaves (TF-FVII/FVIIa) activating factor IX and factor X of 
the coagulation cascade. Activation of this pathway can be counteracted by tissue 
factor pathway inhibitor (TFPI) by inhibiting the TF-FVIIa complex (LWALEED & 
BASS, 2006). TFPI fused to the membrane anchor of CD4 receptors was thus 
expressed on the cell surface of mouse fibroblasts and demonstrated that TFPI does 
not lose activity in the tethered form (RIESBECK et al., 1997). In a murine heart 
transplantation model tethered TFPI was expressed on donor ECs and showed that 
platelets and fibrinogen were in normal levels and that coagulation was prevented 
(CHEN et al., 2004). Lin and colleagues demonstrated the ability of TFPI to inhibit TF 
activity in vitro (LIN et al., 2010) and knockdown of TF expression showed to reduce 
coagulation process in transgenic pigs (AHRENS et al., 2015b). 
In the procoagulant state, porcine endothelial cells release von Willebrand factor, 
which induces the aggregation of human platelets and results in deposition of fibrin 
polymers due to thrombin enzymatic activity  (SCHULTE AM ESCH et al., 2005). 
Normally this coagulation process is blocked by activated protein C, which is produced 
by a complex of thrombomodulin (TBM) on the vessel wall and thrombin (TB) in the 
blood stream. In the xeno situation, however, porcine TBM and human TB fail to 
activate protein C (TAYLOR et al., 2001; ROUSSEL et al., 2008). Expression of 
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human TBM (hTBM) on the surface of porcine endothelial cells led to high quantity 
production of protein C (KOPP et al., 1998). Similarly, hTBM transgenic pig 
fibroblasts were effective in preventing clotting (PETERSEN et al., 2009; MIWA et 
al., 2010). In addition to thrombomodulin, endothelial cell protein C receptor (EPCR) 
is important for the activation of protein C. In large vessels EPCR increases the 
concentration of protein C in the vicinity of the TM/TBM complex but inside 
capillaries where the initial thrombosis process in xenografts takes place the 
concentration of EPCR is very low (STEARNS-KUROSAWA et al., 1996; 
FUKUDOME et al., 1998; TAYLOR et al., 2001). As its function is further decreased 
by the presence of non-Gal antibodies (BYRNE et al., 2011), EPCR expression 
became an option to overcome coagulation disorders (LEE et al., 2012; IWASE et al., 
2014a; GOCK et al., 2016).  
Activated platelets secrete adenosine diphosphate, which recruits and aggregates other 
platelets and boosts the thrombosis mechanism (IWASE et al., 2014b). CD39, a 
nucleoside triphosphate diphosphohydrolase (NTPDase), is expressed on inactive 
endothelial cells and hydrolyzes ATP and ADP into AMP (KACZMAREK et al., 
1996). Studies in mouse models have shown that the overexpression of CD39 can 
prevent renal ischemia reperfusion injury (CRIKIS et al., 2010) and thrombosis 
although bleeding time in CD39 transgenic mice was prolonged causing hemorrhagic 
shock (DWYER et al., 2004). The protection through CD39 was tested in pig as well 
as in an in vivo model of myocardial ischemia reperfusion injury where reduction in 
infarct size was observed (WHEELER et al., 2012).  
2.5.  Systemic drugs 
Using systemic drugs was the first approach tested to prevent xenograft rejection even 
before genetically modified pigs became available (REEMTSMA et al., 1964). As 
these drugs were highly immunosuppressant and highly toxic for the recipient, this 
regimen was not clinically acceptable. As described in the previous paragraphs, 
genome engineering of the xenograft donor has the ability to resolve many 
immunological hurdles in xenotransplantation, but they until now are not sufficient to 
fully prevent rejection. Therefore, it is still necessary to modulate the adaptive immune 
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response by immunosuppressive drugs. Typically such drugs are directed to limit T 
lymphocytes activation by blocking costimulatory signals via anti-CD154 monoclonal 
antibodies (HIGGINBOTHAM et al., 2015) and by the depletion of B lymphocytes 
through proliferation inhibition and apoptosis induction via anti-CD20 mAbs 
(MATHAS et al., 2000; MOHIUDDIN et al., 2012). Because of its pro-thrombotic 
side effects (KUWAKI et al., 2004), anti-CD154mAb is preferentially replaced by 
anti-CD40 mAb (BUHLER et al., 2000). T- and B-cells activation is prevented by 
continuous application of  mycophenolate mofetil (MMF) in combination with 
cyclosporine A and corticosteroids (COZZI et al., 2003; IWASE & KOBAYASHI, 
2015). 
2.6.  The state of the art 
Many combinations of genetically modified donor pigs and systemic 
immunosuppression have been explored, but until recently success was limited. 
Nowadays, however, new optimism has taken the field. This is best exemplified by 
heart xenotransplantation. In a heterotopic heart transplantation setting in baboons, 
grafts survived for more than 2 years using GTKO, hCD46, hTBM pigs and the 
immunosuppressive regimen described above (MOHIUDDIN et al., 2012; 
MOHIUDDIN et al., 2016). However, in this case the heart was transplanted in the 
abdomen and did not have any physiological function. In a life-supporting setting 
survival time was prolonged till 6 months (LANGIN et al., 2018). Life-supporting 
kidney transplantation into macaques reached 499 days using a GTKO/CD55 donor 
pig in association with anti-CD154mAb, anti CD4mAb, MMF and corticosteroids 
(KIM S, 2017). In contrast, liver and lung xenotransplantation seems to be more 
difficult. The longest liver survival time is 29 days (SHAH et al., 2017), when livers 
from GTKO pigs were transplanted into baboons, accompanied by continuous infusion 
of prothrombin in addition to an immunosuppressive regimen consisting in anti-
CD40mAbs, ATG and corticosteroids. For lung, donors with different combinations 
of genetic modifications were tested and 9 days maximal survival time was achieved 
for GTKO pigs and hCD47/hCD55 expression in alveolar epithelial and capillary cells 
and pulmonary arterial endothelium (WATANABE et al., 2018).  
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Besides whole organ xenotransplantation, progress was made for transplantation of 
pancreatic Langerhans islet cells, important for the type 1 diabetes treatment. The 
longest control of blood glucose homeostasis for up to 6 months was achieved through 
intraportal transplantation of islets isolated from Seoul National University miniature 
pigs into streptozotocin-induced diabetic rhesus monkeys, using a moderate 
immunosuppressive protocol with anti-CD154 mAbs, ATG and sirolimus (SHIN et 
al., 2015). To reduce administration of immunosuppressive drugs, physical separation 
of the islets from the recipient was investigated (CUI et al., 2009; DUFRANE et al., 
2010). Islets from Goettingen minipigs were encapsulated in BetaO2 devices and 
transplanted for 6 months into nonhuman primates (LUDWIG et al., 2017). Glucose-
regulated insulin secretion and absence of immunoreaction events without requirement 
of immunosuppressive regimen was demonstrated. Till now only the transplantation 
of islets was tested in a clinical trial. In 2009 in New Zealand patients with severe 
unaware hypoglycemia were transplanted with Diabecell or rather neonatal islets 
encapsulated in alginate microcapsules. The patients showed amelioration  in the 
severity of the hypoglycemic episodes and stable glucose levels (GARKAVENKO et 
al., 2012). 
3. Safety of xenotransplantation 
With the recent progress in preclinical studies, the application of xenotransplantation 
in human patients appears realistic in the next decade. However, for such an 
undertaking, safety concerns need to be resolved. Most importantly, transmission of 
pathogens from the donor to the human recipient needs to be prevented. Xenozoonose 
are assumed to represent an even higher safety risk than infection in allotransplantation 
(DENNER & TONJES, 2012), although human allotransplantation resulted in 
infection with human immunodeficiency virus, human cytomegalovirus (HCMV), 
hepatitis C virus (HCV), human T cell lymphotropic virus (HTLV), Mycobacterium 
tuberculosis, Candida and other bacteria and fungi at considerable rates (FISHMAN 
et al., 2012b). The unforeseeable consequence of transmission of infectious agents 
across species barriers raised severe concerns about the clinical perspectives of 
xenotransplantation. The use of systemic immunosuppressant regimen can further 
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facilitate the infection ability of microorganisms. For instance, porcine 
cytomegalovirus (PCMV) might be dangerous for the human recipient as it was shown 
to infect a human fibroblasts cell line in vitro (WHITTEKER et al., 2008). Moreover, 
the infection with PMCV was associated with reduced graft survival in kidney 
transplantation into baboons (YAMADA et al., 2014) or into Cynomolgus monkeys 
(SEKIJIMA et al., 2014). Absence of PMCV coincided with prolonged porcine heart 
survival and prevented consumptive coagulopathy in the recipient (MUELLER et al., 
2004).  
On the other hand and in contrast to allotransplantation, where microbiological 
screenings of donors  are difficult to apply due to the narrow time window between 
explantation and implantation (NELLORE & FISHMAN, 2018), there would be 
enough time to screen xenograft donors before transplantation (DENNER & 
MUELLER, 2015).  
To eliminate the risk of infection in xenotransplantation, the donor has to be free from 
microorganisms like bacteria, fungi, protozoa and especially viruses. Therefore, it is 
important to establish adequate and sensitive screening protocols (FISHMAN & 
GROSSI, 2014). For addressing these issues, the World Health Organization (WHO) 
recommended to regulate safety aspects of Xenotransplantation before clinical 
application (DENNER, 2017). Regulations and guidelines considering the 
“Precautionary principle”, as postulated by the Food and Drug Administration (FDA) 
and the European Medicines Agencies (EMEA) specify surveillance programs and 
safety standard operation procedures concerning screening for the source pigs and 
materials derived from them (FISHMAN et al., 2012a; SPIZZO et al., 2016; 
NOORDERGRAAF et al., 2018; TONJES, 2018). Evidently, designated pathogen-
free (DPF) breeding conditions are required for the production of donor pigs. Most 
microorganisms like bacteria and fungi as well as many viruses can be eradicated with 
antibiotics, anti-fungal treatments, vaccines, antiviral drugs and DPF conditions can 
be established by Cesarean delivery and early weaning (EGERER et al., 2018). 
Unfortunately, some pathogens such as the porcine gammalymphotropic herpesvirus 
(PLHV) cannot be eradicated by these means and other methods have not been 
suggested so far (MUELLER et al., 2005; DENNER & MUELLER, 2015).  
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Maintenance of DPF status has to be confirmed routinely by regular screening of the 
production herd for infectious microorganisms and viruses (SPIZZO et al., 2016). For 
example, the donor herd used in New Zealand for the first clinical trial of porcine islet 
cells transplantation were quarterly or annually tested for 10 bacteria, 15 viruses and 
1 protozoon (WYNYARD et al., 2014). In addition, to assure a clean porcine material 
for xenotransplantation, sensitive detection assays and new screening methods are 
important for the identification of new virus infections as they could be present in the 
xenograft in low quantity or could be in a latent phase of their life cycle 
(DENNER,2017; HARTLINE et al., 2018).  
3.1.  Retroviruses 
Common eradication strategies fail to remove viruses that are permanently integrated 
into genome, specifically porcine endogenous retroviruses (PERV) (ONIONS et al., 
2000). Among RNA viruses, retroviruses have the special feature of being able to 
reversely transcribe their RNA genome into double stranded DNA and to integrate this 
DNA as provirus into the host genome.  Retroviruses comprise viruses with relatively 
complex genomes like lentiviruses, deltaviruses and spumaviruses as well as viruses 
with very  simple genomes like alpha, beta, gamma and epsilon retroviruses (WEISS, 
2006). Viruses that contain RNA genomes were discovered in 1961 when the Rous 
sarcoma virus was isolated (CRAWFORD & CRAWFORD, 1961). The name 
retrovirus was chosen after that reverse transcriptase enzyme was discovered (TEMIN 
& MIZUTANI, 1992). All retroviruses consist of phospholipid envelope which 
embeds viral envelope (env) proteins. env constitutes two parts, the transmembrane 
(TM) component which is anchored in the membrane as well as the surface (SU) 
protein which facilitates uptake into host cells and, thus, defines the tropism of the 
virus (COFFIN, 1997; VOGT, 1997). Within the phospholipid envelope, the virion 
consists of a capsid formed by the nucleocapsid protein. This capsid protects the core 
of the virus comprising the reverse transcriptase, protease and integrase as well as two 
copies of the RNA genome. In addition to protecting the virus core, nucleocapsid 
proteins play an important role during reverse transcription due to their chaperone 
function (RENE et al., 2018). The virions have in general a diameter of 80-100 nm, 
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but the protein content of the core is different in the distinct retrovirus genera. Simple 
retroviruses do only comprise three different genes, gag, pro/pol and env encoding the 
nucleocapsid, reverse transcription components and the envelope proteins. In contrast, 
more complex retroviruses encode additional genes which, for example, facilitate the 
integration into non-dividing cells (COFFIN, 1997).  
The life cycle of a virion starts with the infection of a host cell. In the early phase the 
virion envelope fuses with the host cell membrane through binding of receptors and 
attachment factors on the host cell surface. Upon internalization into the cytoplasmic 
space, the virus starts its reverse transcription to a double strand cDNA which 
integrates as provirus in the host chromosomal DNA by the viral integrase (NISOLE 
& SAIB, 2004; JERN & COFFIN, 2008). The dsDNA of simple retroviruses like 
Murine Leukemia Virus (MuLV) needs the breakdown of nucleus membrane for 
entering the nucleus (GOFF, 2001). Once integrated, the provirus starts to transcribe 
the entire viral genome taking advantage of the host RNA polymerase II as well as 
non-coding small RNAs which have modulation activity on viral and cellular gene 
expression (JERN & COFFIN, 2008; ZHANG et al., 2018). From the viral RNA, the 
cellular translation machinery translates the viral proteins. The virion’s elements are 
transported to the cytoplasmic space nearby the phospholipid bilayer where the 
assembly process of the viral core is initiated. The capsid is then enveloped by the host 
cell membrane, comprising the TM and SU, releasing the virion via membrane fission 
or budding as a new viral particle (COFFIN, 1997; WELSCH et al., 2007).  
Mostly, retroviruses infect somatic cells and, thus, are transmitted horizontally from 
host cell to host cell. Therefore, they are called exogenous retroviruses. When 
retroviruses infect germline cells, the integrated provirus becomes an endogenous 
retrovirus (ERV). Upon infection, germline cells can evidently produce intact virus 
particles, similar to somatic cells. In addition, however, proviruses can be transmitted 
to the offspring as integral components of the germ cell genome. Therefore, ERV are 
said to be vertically transmitted (KATZOURAKIS & GIFFORD, 2010).  
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3.2.  Endogenous retroviruses 
The first ERV have been identified about 10 years after the discovering of retroviruses 
when vertical transmission of murine leukemia virus (MLV),  murine mammary tumor 
virus (MMTV) in the laboratory mouse (Mus musculus) and avian leukosis virus 
(ALV) in the domestic fowl (Gallus gallus) was documented (WEISS, 2006). With 
the establishment of molecular genetic techniques, like DNA hybridization, PCR and 
DNA sequencing, ERV were found in any vertebrate examined so far. In humans, ERV 
represent up to 8% of the genome, illustrating that the integration of retroviruses is a 
frequent process and relevant in evolution (LANDER et al., 2001; GIFFORD & 
TRISTEM, 2003; MAGER & STOYE, 2015). ERV have a common genetic 
composition comprising an LTR-gag-pro/pol-env-LTR structure. Once integrated into 
the germline, ERV behave like other transposable elements, which might result in the 
increase of  copy numbers (GRIFFITHS, 2001). On the other hand, the faith of ERV 
after integration into the germ line is dominated by the effect of ERV on host evolution. 
In the case of a detrimental effect, negative selection causes the extinction of the host 
and, thereby, also of the provirus. In the case of a neutral selection, ERV remain in the 
genome, are transmitted vertically and accumulates mutations like insertions, 
deletions, rearrangements and epigenetic silencing, leading to inactivation of ERV and 
the loss of the ability to produce infectious virions (BOEKE & STOYE, 1997). 
Importantly, parts of ERV might also have beneficial function on host and, therefore, 
underlie positive selection (VARELA et al., 2009). One of the best evidence of 
beneficial function is the placental expression of HERV-W and HERV-FRD env genes 
(the only ORF conserved) which generate the fusion of  cytotrophoblast in human (MI 
et al., 2000; BLAISE et al., 2003). Similar fusogenic proteins derived from ERV are 
found in murine species as well (DUPRESSOIR et al., 2005). Another example for 
beneficial ERV function is the specific expression of  the salivary amylase gene 
(AMY1C) in the parotid gland due to the presence of the endogenous retroviral derived 
element ERVA1C in the proximity of the AMY1C gene promoter (TING et al., 1992). 
Proteins expressed from ERV genes can also induce resistance against exogenous 
retrovirus infection by behaving as restriction factor. The binding of env product to a 
cellular receptor interferes and inhibits the surface attachment of new virus through 
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downregulated expression and saturation of cell receptors (MCDOUGALL et al., 
1994; WU et al., 2005). The murine Friend virus susceptibility -1 (Fv1) gene for 
example has 40% sequence similarity with the gag gene of murine ERV-L (MERV-L) 
and inhibits MLV and non-MLV infection (SANZ-RAMOS & STOYE, 2013; YAP et 
al., 2014).  
Like in other mammals, ERV were found in the pig (PERV), the preferred species for 
xenotransplantation. Different types of PERV from α, β and γ classes have been 
identified, but only γ type viruses have been shown to be infectious (PATIENCE et 
al., 1997; PATIENCE et al., 2001; GROENEN et al., 2012). Replication competent 
PERV were observed for the first time in a porcine kidney cell line (PK15) 
(ARMSTRONG et al., 1971). The determination of PERV copy number by genomic 
mapping, cDNA screening or droplet digital polymerase chain reaction (ddPCR) in 
different pigs indicate that there is a different number of PERV among pig breeds and 
that the number of PERV ranges from 10 to 134 (AKIYOSHI et al., 1998; HERRING 
et al., 2001; FIEBIG et al., 2018). As in all ERV, the general genomic organization 
comprises 3 ORF containing genes enclosed by non-coding sequences on the 5’ and 
3’ end. Reverse transcription is induced by the binding of a specific tRNA in the so-
called primer binding site near the 5´ end of the viral RNA genome. For PERV A and 
PERV B this tRNA is a tRNAGly and for PERV C is tRNAPro (VOGT, 1997; 
BARTOSCH et al., 2002). Synthesis of the primary DNA strand continues to the 5´ 
end, including the R and U5 region. Then the primary strand is transferred to the 3´end 
of the viral genome, where an identical R sequence is found. First strand synthesis is 
again continued to the 5´end, resulting in identical U3-R-U5 elements (LTR) at both 
ends of the provirus. Therefore, the PERV comprise the common LTR-gag-pro/pol-
env-LTR structure (STOYE, 2012; KIMSA et al., 2014). Importantly, the initially 
identical LTR of a provirus facilitates estimating the time point of integration, because 
mutations in the LTR accumulate over time, when neutral selection is assumed. Based 
on the molecular clock hypothesis this event found state approximately 7,6 million 
years ago (TONJES & NIEBERT, 2003). Between the 5´LTR and the coding region 
of gag, non-translated segments of regulatory function are located. These components 
are the primer binding site (PBS), the splice donor (SD) site as well as the packaging 
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signal psi Ψ which is essential for the packaging of the viral RNA genome into the 
virion capsid (CHOI et al., 2015; LOPATA et al., 2018). The presence of all 3 intact 
viral genes, gag, pro/pol and env, in the coding region is prerequisite for the formation 
of replication competent ERV. The gag gene encodes for a precursor protein that forms 
the viral core. The pro/pol gene encodes protease, reverse transcriptase and integrase 
enzymes, responsible for the generation of dsDNA and its integration into host 
chromosomes (DENNER & TONJES, 2012). The env gene encodes the surface and 
transmembrane envelope protein and is expressed as a polyprotein that is glycosylated 
in the host cell on multiple sites (AKIYOSHI et al., 1998; LEE et al., 2006). 
Importantly, the gag and pro/pol genes are highly conserved among active PERV 
whereas significant differences have been found in the env gene, resulting in different 
tropism and the consequent definition of the subfamilies A, B and C (LE TISSIER et 
al., 1997; AKIYOSHI et al., 1998; TAKEUCHI et al., 1998; PATIENCE et al., 2001).  
3.3.  Pathogenic potential of ERV 
Replication competent ERV can lead to pathological conditions and similarly to most 
retroviruses, most ERV have been identified upon their pathogenic effect on the host. 
Like already described for exogenous retroviruses, ERV can cause disease and cancer 
via different mechanisms (STOYE, 2012; KASSIOTIS, 2014). Active ERV integrate 
in the host genome in a random manner which can result in an insertional activation 
of protooncogenes, downregulation of tumor suppressor genes, mutation or destruction 
of genes with consequent loss or gain function (MAGER & STOYE, 2015). It is of 
note that endogenized forms of PERV-related murine leukemia virus (MuLV), feline 
leukemia virus (FuLV) and gibbon ape leukemia virus (GaLV) have tumorigenic and 
immunodeficiency potential. These retroviruses possess a region of transmembrane 
envelope protein (TM), called immunosuppressive domain, which was shown to 
inhibit in vitro a few of different immune responses like mitogen stimulated 
lymphocyte proliferation and mitogen-induced proliferation of human PBMC 
(HARAGUCHI et al., 1997; DENNER, 1998; TACKE et al., 2000). For PERV itself 
however, tumorigenic and immunodeficiency potential has not been described so far 
(ROSENBERG & JOLICOEUR, 1997; DENNER, 1998; TACKE et al., 2000). 
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Although, in Munich miniature swine Troll, a model for hereditary cutaneous 
melanoma, high expression of recombinant PERV-A/C has been detected in the 
diseased pigs compared to healthy controls (DIECKHOFF et al., 2007). Even defective 
ERV can be involved in disease when they recombine with an exogenous virus 
(ROSENBERG & JOLICOEUR, 1997). Another possibility of pathogenic effects of 
ERV is when they express viral proteins that act as a superantigen and, thus, cause 
autoimmune disease (SICAT et al., 2005; KATOH & KURATA, 2013). Even solo 
LTR can influence genome activity by acting as an enhancer to adjacent genes (JERN 
& COFFIN, 2008; WEISS, 2016).  
Considering all these potential pathological effects and the potential transmission of 
retroviruses from one species to another as well as the fact that PERV are replication 
competent, it is important to consider pathogenicity risks of PERV in 
xenotransplantation (ARMSTRONG et al., 1971; DENNER, 2007). The finding that 
different human cell lines (PATIENCE et al., 1997) as well as primary human 
endothelial cells (MARTIN et al., 2000) were infected by PERV released from the 
PK15  porcine kidney cell lines was of outstanding importance. In the field of 
xenotransplantation in addition, human cell lines were permissive to PERV produced 
from primary porcine peripheral blood mononuclear cells (PBMC) (WILSON et al., 
1998) as well as from porcine primary aortic endothelial cells (PAEC) (MARTIN et 
al., 1998). Specifically, PERV-A and PERV-B are able to infect human cells in vitro 
as well as pig cells (LE TISSIER et al., 1997). In contrast, PERV C alone is an 
ecotropic ERV that infects only pig cells, (AKIYOSHI et al., 1998; TAKEUCHI et al., 
1998; PATIENCE et al., 2001). When recombining with PERV A, however, PERV C 
can contribute to a super-infectious PERV A/C, that highly effectively infects human 
cells (OLDMIXON et al., 2002; BARTOSCH et al., 2004). The enhanced infectivity 
of PERV-A/C (titer 500 fold higher than PERV A) is associated with mutation of  
isoleucine into valine in the 140 position in the  PERV A derived receptor binding site 
(RBD) and the PERV C derived proline reach region (PRR) (HARRISON et al., 2004). 
Moreover, 4 specific residues in the PERV C derived terminus of SU promote infection 
of human cells through the interaction with receptors HuPAR 1 and HuPAR 2. 
Therefore, it can be  postulated that spontaneous mutations can induce switching of 
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ecotropic PERV C in to a human-tropic PERV (ERICSSON et al., 2003; 
GEMENIANO et al., 2006; ARGAW et al., 2008). In addition, increasing the viral 
titer through serial passaging in human cells facilitates productive infection on human 
primary cells like pulmonary artery endothelial cells (HPAEC), aortic endothelial cells 
(HAEC), human peripheral blood mononuclear cells (PBMC) and human lymphocytic 
cell lines C8166 by PERV A/C (SPECKE et al., 2001b; SPECKE et al., 2001a). This 
increase in viral titer of PERV is related to the extension of the LTR length  as a 
consequence of  multiplication of direct repeats, which act as transcription factor 
binding sites and therefore enhance the activity of retroviral promoters (DENNER et 
al., 2003; DENNER, 2015). The incapability of PERV produced freshly from porcine 
cells to infect hPBMCs is due to the inability of PERV to overcome protective factors 
like APOBEC and Tetherin (DORRSCHUCK et al., 2011; BAE & JUNG, 2014; 
DENNER, 2015). This finding might explain why till now there are no evidences for 
PERV infection in different patients who have received porcine materials. It is of note 
that any of these studies have shown the transmission of the porcine-human species 
barrier only in vitro. In contrast, retrospective studies  in over 200 human recipients of 
porcine skin, fetal neuronal cells, encapsulated and neonatal islet, extracorporeal 
kidney and liver perfusion, aortic valves etc. did not reveal PERV RNA, DNA or 
antibodies against PERV (PARADIS et al., 1999).  
Studies of PERV infection and transmission were also done in other species, including 
non-human primates in which xenotransplantation preclinical studies are performed. 
Again, neither antibodies production and virus reproduction nor transmission of PERV 
has been demonstrated so far (PLOTZKI et al., 2015; DENNER, 2018). The lack of 
PERV infection seems to result from non-functional cell receptors for the first PERV-
cell interaction (MARTINA et al., 2006; MATTIUZZO et al., 2007; MATTIUZZO & 
TAKEUCHI, 2010; PLOTZKI et al., 2015). Therefore, it remains important to study 
the pathogenicity and infection mechanisms of PERV and to minimize or delete the 
infection risks from PERV. In particular, it will be important to provide donor pigs 
that are free of PERV C to avoid the generation of high titer of PERV A/C. 
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4. PERV deletion approaches 
To minimize the infectious risk from PERV for pig xenograft recipients the first thing 
to do is to select donor pig that have the lowest possible copy number of PERV C in 
their genome. By using screening methods like PCR, nested PCR, real time PCR (RT- 
PCR), reverse transcriptase RT-PCR or co-culture pig-human cell assays it was found 
that the copy number of PERV C in pigs is generally low and even PERV C free pigs 
have been identified (DENNER et al., 2009; KAULITZ et al., 2011b; FIEBIG et al., 
2018). Most existing genetically modified donor pigs for xenotransplantation, 
however, contain PERV C proviruses. Different PERV inactivating approaches might 
reduce the risk of transmission. As for other gamma retroviruses, the establishment of 
vaccines against PERV can protect the human recipient. First PERV vaccines have 
been developed on the basis of neutralizing antibodies against membrane proximal 
external region in the N-terminal of the TM envelope protein    (FIEBIG et al., 2003; 
KAULITZ et al., 2011a; WAECHTER & DENNER, 2014). Simultaneous 
immunization with TM and SU proteins revealed a higher neutralizing activity as with 
the respective proteins alone (DENNER et al., 2012). Other strategies target PERV at 
the nucleic acid level. For example, the inhibition of PERV expression might be 
mediated through short interfering RNA (siRNA), a mechanism which is known to be 
common in eukaryotic cells to suppress protein synthesis and to act as anti-viral 
responses (CAPLEN et al., 2001). siRNAs are double strand RNA components with a 
length of about 22 nucleotides. They are recognized by RNA induced silencing 
complex (RISC) which induces the degradation of RNA targets that are homologous 
to the siRNA (YANG et al., 2000). Different studies were conducted by introducing 
siRNA against conserved regions of PERV into PERV-infected human cell lines 
(KARLAS et al., 2004), porcine cells (MIYAGAWA et al., 2005) and in vivo in 
transgenic pigs (DIECKHOFF et al., 2008; RAMSOONDAR et al., 2009). All these 
attempts worked efficiently and demonstrated that pol siRNA expressed in transgenic 
pigs reduced PERV expression over 3 years without adverse effects (SEMAAN et al., 
2012).  
Alternatively to the RNA level, PERV can be inactivated also at the genomic level by 
the novel technique of genome editing. Such an attempt provides the most sustainable 
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effect by introducing deleterious mutations into the provirus. This inactivation can be 
induced by zinc-finger nucleases (ZFNs) which induce double strand breaks (DSB). 
After this break, the affected cell activates DNA repair processes like the error prone 
non-homologous end joining (NHEJ) (KIM et al., 1996b; RAMALINGAM et al., 
2013) or the faithful homologous recombination (HR) (RICHTER et al., 2013). NHEJ 
often results in small deletions or insertions in the cut location which often cause a 
frameshift and the consequent generation of stop codons while the HR mechanism can 
be advantageous to introduce new DNA sequence having flanking regions 
homologous to the sequences present upstream and downstream of the DSB break 
(RAMALINGAM et al., 2013; MAHFOUZ et al., 2014). Considering the successful 
generations of knock out pigs using gene editing with ZFNs (KIM et al., 1996b; 
HAUSCHILD et al., 2011; BAO et al., 2014) this technology was used to delete PERV 
proviruses integrated in the genome. The only attempt for ZFN reported so far, 
however, failed because the multiple DSB destabilized the cell genome bringing the 
cell to die (SEMAAN et al., 2015). Meanwhile, ZFN and the related TALEN 
technologies have been outdated by the much more flexible CRISPR/Cas 
endonuclease. 
4.1.  Inactivation by CRISPR/Cas9 
Described for the first time in 1987 in Escherichia coli, this system is a natural adaptive 
immune response that bacteria and archaea have developed to protect themselves from 
viral and plasmid sequences (ISHINO et al., 1987). First step in this adaptive process 
is the integration of exogenous viral or plasmid DNA at a length of 20-30 bp into the 
so-called clustered regularly interspaced short palindromic repeats (CRISPR) locus in 
the bacterial genome. After integration of the exogenous DNA, the RNAs (crRNA) are 
expressed and activate CRISPR associated endonucleases(Cas) RNA dependent by 
annealing to the trans-activating crRNA (tracrRNA) (HORVATH & BARRANGOU, 
2010; RAMALINGAM et al., 2013; AHMAD et al., 2018). The Cas protein is then 
directed to its target site by the specific binding of crRNA to its complementary strand 
in newly invading viruses. Eventually the virus is inactivated through cleavage by the 
Cas protein (MOJICA et al., 2000; JANSEN et al., 2002). A useful adaptation of this 
 
 
 
 
II. Review of Literature 21 
 
 
 
system is the possibility to produce a guide RNA (gRNA) which acts as crRNA and 
tracrRNA at once (CHO et al., 2013; CONG et al., 2013; MALI et al., 2013). Thus, 
for biotechnological purposes mostly a two-component system is used: the Cas9 
protein and a synthetic gRNA. In addition to the desired DSB of the target sequence, 
cleavage can also occur unspecifically at so-called off target sites because 
CRISPR/Cas9 system tolerates up to 5 mismatches within the 20 bp recognition site 
(FU et al., 2013). However, the genome editing specificity by this system can be 
improved by double nicking strategy which combines a pair of gRNAs guiding two 
mutated Cas9 nickases to cleave the two strands of the target site separately (RAN et 
al., 2013). Alternatively, mutated Cas proteins with higher specificity have been 
developed (KLEINSTIVER et al., 2016; IDOKO-AKOH et al., 2018). Since its 
discovery, CRISPR/Cas9 genome editing system has been used for many different 
purposes in different fields and after the first application in targeting mammalian genes 
(CONG et al., 2013) this approach became an important tool in xenotransplantation to 
generate knockout pigs (PETERSEN et al., 2016; CHO et al., 2018) or knock-in pigs 
(WANG et al., 2015), to delete multiple genes simultaneously (WANG et al., 2016), 
and to exchange porcine genes with its human ortholog (NUNES DOS SANTOS et 
al., 2018). In addition, it would be interesting to use the CRISPR/Cas system  also to 
insert xenoprotective genes that simultaneously inactivate unwanted genes like already 
performed with other gene editing approaches (KWON et al., 2017; NOTTLE et al., 
2017). The multiple gene editing ability of CRISPR/Cas has been used to reduce PERV 
infectious potential by inactivating all PERV copies present in the pig genome. Two 
studies inactivated PERV, first in a porcine kidney cell line PK15 (YANG et al., 2015) 
and then in a primary porcine fetal fibroblast cell line (FFF3) (NIU et al., 2017). In 
both cases, certain cell clones were identified in which all PERV were successfully 
inactivated by insertion and deletion events. In the PK15 cells the PERV copy number 
was 62 while in the FFF3 it was 25. In cells with all PERV inactivated no reverse 
transcriptase (RT) activity and no off target effect were shown. The FFF3 cells were 
then used to clone embryos and to transfer them into surrogate sows which generated 
PERV inactivated healthy piglets (NIU et al., 2017). It is of note that in both studies, 
neither porcine cells nor the foster mother did contain any PERV C proviruses. 
Considering the pathogenicity risk of recombinant  PERV A/C it would be, however, 
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important to perform such CRISPR/Cas9 inactivation experiments in cells containing 
also PERV C (SCOBIE et al., 2017). The inactivation of all PERV integrated in a 
genome presents the risk of chromosomal aberrations and requests high effort and may 
be not necessary since only few PERV might be active. Therefore, the excision of 
PERV C is a good strategy to prevent the recombination with PERV A. 
4.2.  Mapping PERVs integration sites 
To inactivate or to delete PERVs function there is no ultimate need to identify their 
exact location in the porcine genome, but excision of the entire provirus requires at 
first the identification of their integration site. PERV integration sites can be explored 
by mapping fragments of genomic DNA of a certain pig through publicly accessible 
reference genomes (LUFINO et al., 2016). Different approaches were used to generate 
pig libraries on the basis of BAC, lamda phages or cosmids (ROUQUIER et al., 1993; 
WANG et al., 2003). In fact, BAC libraries were used for the first pig genome 
sequencing project (GROENEN et al., 2012). The bacterial artificial chromosome 
(BAC) is a highly stable circular self-replicating vector conserved in E.coli. BAC 
facilitates cloning of large DNA fragment from 100 to 300 kb  and thus allows 
identification of the adjacent genomic region of a provirus (SHIZUYA et al., 1992; 
KIM et al., 1996a). For identifying PERV containing BAC, clones are screened for the 
sequence of interest (the provirus) by using labelled probes. BAC-end sequencing can 
be performed to localize the position of the BAC on the reference genome (YU et al., 
2012). Mapping and characterization of PERV in the porcine genome using different 
vector for the construction of DNA libraries have already been done (C. ROGEL-
GAILLARD, 1999; HERRING et al., 2001; NIEBERT et al., 2002).  In these studies, 
DNA libraries from a Large White pig were screened to identify intact PERV by 
Southern blotting, inverse PCR and sequencing. The integration sites or proviral 
flanking sequences were characterized through linker-mediated PCR methods with a 
primer in the PERV LTR and a primer within blunt-end-cut of DNA vector in order to 
enable the identification of their chromosomal locations (SIEBERT et al., 1995). The 
LTR flanking region were than used to design primers useful to explore the PERV 
prevalence in different hDAF transgenic Large White pig (HERRING et al., 2001). 
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The number of potentially functional PERV found in the Large White pig is low and 
there is no evidence for the presence of PERV C. However, PERV have been further 
characterized using DNA libraries from different type of pigs (LEE et al., 2002; JUNG 
et al., 2010) like in National Institutes of Health miniature pigs which appeared to 
contain also PERV-C (YU et al., 2012). Nevertheless, BAC library construction and 
all subsequent work need considerable amounts of time and resources to identify 
possible integration site of a specific PERV.  
A new strategy seems to be more efficient in localizing of a given genomic structure  
using only genomic DNA (DE VREE et al., 2014). This strategy is called targeted 
locus amplification (TLA) which in principle combines inverse PCR with next 
generation sequencing and permits analysis of genomic regions of around two hundred 
kilobases. TLA is based on the principle that genomic vicinity on the DNA strand 
sequences does also result in spatial 3D vicinity in the nucleus, and therefore can be 
stabilized by cross-linking. After fragmentation and religation circular DNA is 
obtained. Following the inverse PCR principle, primers are then used which bind in 
the known sequence (i.e the provirus) but are directed a part from each other. PCR thus 
amplifies the adjacent region of the provirus. The amplified fragments are then 
sequenced to reconstruct the locus of interest. Different studies have shown the 
efficiency of TLA technology to map transgenes integration sites, breakpoints induced 
by transgenes integration and local structural changes (CAIN-HOM et al., 2017; 
TOSH et al., 2017) as well as to make prenatal diagnosis (VERMEULEN et al., 2017) 
and genetic screening in acute leukemias (KUIPER et al., 2015; ALIMOHAMED et 
al., 2018). Considering the characteristics of this approach, TLA can be used to map 
and to detect the integration sites of a sequence of interest like for example a provirus 
at base-pair resolution. 
Considering the known information about structural PERV sequences, the pathogenic 
potential of PERV and the preference of PERV C absence in donor pigs for 
xenotransplantation (https://www.who.int/transplantation/xeno/en/), the targeted 
locus amplification can be used together with CRISPR/Cas9 genome editing tool to 
identify and characterize the integration sites of PERV C in our herd and to design 
guide RNAs used from CRISPR/Cas9 to excise PERV C definitively from the genome 
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of somatic cells obtained from a pig carrying the lowest PERV C copy number. This 
and the screening of all our bred animals for the identified PERV C integration sites 
in order to support their removal as well as by breading was the aim of this research 
work. 
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III. Materials and Methods 
1. Materials 
1.1.  Devices 
Name Manufacturer 
Accu-jet pro pipette controller Brand, Wertheim 
Agarose gel electrophoresis chamber WG - Biotech, OWL Inc., USA 
Benchtop 96 tube rack Stratagene, USA 
Biochrom™ SimpliNano Spektrometer Biochrom GmbH, Berlin 
Biofuge pico centrifuge Heraeus, Osterode 
Centrifuge 5415 D Eppendorf, Hamburg 
Centrifuge 5810 R Eppendorf, Hamburg 
Centrifuge 5417 R Eppendorf, Hamburg 
Centrifuge Labofuge M Heraeus, Osterode 
Cellavista SynenTec, Münster 
Centrifuge Rotina 380R Hettich, Tuttlingen  
Cell CO2 incubator MMM Group, Munich 
CoolCell BioCision, USA 
Centrifuge Spectrafuge 24D Labnet International, USA 
EASYpure® II pure aqua, Schnaitsee 
Gel documentation system BioRad, Munich 
Geneamp PCR System 9700 thermocycler Applied Biosystems, USA 
GeneQuant Pro spectrophotometer Amersham, Uk 
Glass pipets Brand, Wertheim 
Incubator 37°C and 60°C Memmert, Schwabach 
inoLab® pH meter 7110 WTW, Weilheim 
Laminar flow HB 2448K Heraeus, Hanau 
Laminar flow HeraSafe HS12 Kendro, Hanau 
Mastercycler® gradient Eppendorf, Hamburg 
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MS 5 Stereomicroscope Leica, Wetzlar 
Microwave DAEWOO, Korea 
Pipettes (1000 μL, 200 μL, 20 μL, 10 μL, 2 μL) Gilson Inc, USA 
Power Pac 300 gel electrophoresis unit BioRad, Munich 
Power Station 300 gel electrophoresis unit Labnet International, USA 
RH Basic heating plate with magnetic stirrer IKA, Staufen 
Shaking Incubator GFL, Burgwede, DE 
Select vortexer Select BioProducts, USA 
SilberCycler, 96er mit Gradient Süd-Laborbedarf, Gauting 
Thermomixer 5436 Eppendorf, Hamburg 
Varioklav 400 autoclave H+P Labortechnik, Oberschleißheim 
Thermostat Plus Eppendorf, Hamburg 
Water bath JB Nova Grant Instruments, UK 
Water bath AQUAline AL 12 Lauda-Brinkmann 
 
1.2.  Consumables 
Name Manufacturer 
96-well culture plate Nunclon delta surface, USA 
96-well half area culture plate Corning Costar, USA 
Centrifuge tubes (15 ml, 50 ml) Falcon, Becton Dickinson, Heidelberg 
Cryotubes 1 and 2 ml NuncTM, Denmark 
Cryo vial (0.5 ml, 1.5 ml) TPP, Switzerland 
Disposable sterile culture tubes Simport, Canada 
Glass pasteur pipettes Brand, Wertheim 
Parafilm® M American Can Company, USA 
PCR reaction tubes (0.2 ml) Brand, Wertheim 
Petri culture dishes Sarstedt, Nümbrecht 
Pipet tips Eppendorf, Hamburg 
Pipet tips with filter Thermo Scientific, Schwerten 
SafeGrip® latex and nitril gloves SLG, Munich 
Safe-Lock reaction tubes (1.5 mL, 2 mL) Eppendorf, Hamburg 
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1.3.  Software and Bioinformatic tools 
Bio Edit Sequence Alignment Editor Tom Hall, USA 
Finch TV Version 1.3.1 Geospiza Inc., USA 
Microsoft Office Suite Microsoft, USA 
Cellavista Application software SynenTec, Münster 
Basic Local Alignment Search Tool https://blast.ncbi.nlm.nih.gov/Blast.cgi 
e!Ensembl https://www.ensembl.org 
Primer designing tool https://www.ncbi.nlm.nih.gov/tools/primer-blast/ 
PrimerQuest Tool, IDT https://eu.idtdna.com 
chopchop gRNA http://chopchop.cbu.uib.no/ 
Tm Calculator https://www.thermofisher.com 
Repeat masker http://www.repeatmasker.org/ 
1.4. Kits 
Name Manufacturer 
Double Pure Kombi Kit Bio&SELL, Nürnberg 
NexttecTM Genomic DNA Isolation Kit Nexttec Biotechnologie GmbH 
Easy-DNA™Kit Invitrogen, Karlsruhe 
NucleoSpin®Gel and PCR Clean-up Macherey-Nagel, Düren 
 
1.5.  Oligonucleotides 
 All designed primers and guide RNAs were purchased from Biomers.net GmbH, Ulm. 
Name               forward 5'-3'                  reverse 5'-3' 
PERVC set1 TGGCCTGATCTATACGTTTG CCTATGCGCATACCATTAGT 
PERVC set2 CAACCCAAGGACCAGGAC TCATTAGAGGTTACACAGTTCC 
gRNA 141C51 GCATTATTTTCAGGTCACTG  
gRNA 141C52 GAAGCTTTGAACATGATTCC   
gRNA 141C31 GAATCTTGGTTCCTGGCCCT   
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Name                 forward 5'-3'                  reverse 5'-3' 
EnvC1 CAGTTATTCCTAGTCTGACCTCAC AGCCATTGGAGGCTCCAGCTG 
141int1 AGAGCAGCATTGAGGCAAGG AGTACCAAAGCCCGTCTAGC 
141up2 ATCTCTGCTTTCCTCCCTCTA CGAATAAGTGCAGTCCAGATCA 
141int3 TTTACCTCCAAGTCGGTTCTC CAGCAGGTGAGAGTATGCTATG 
141int4 GATCCTCCTAGCACGTCTGC CCCAGCAGGTGAGAGTATGC 
141exc1 ATTGAGGCAAGGCTGGTTCC TTTCTGTGTTGAGGAACCCCT 
141exc2 ATCTCTGCTTTCCTCCCTCTA CAGCAGGTGAGAGTATGCTATG 
141s1 AGTTTGATGAAGCAAGTATCC ACTCACACTTTGGTTATGG 
141s2 ACTCATTTAGCTTTTTGGTCC AAGGGAGTTTCTAACTGC 
141s3 GGAGACATGTTGTCACC GAATTATTCTTCTACTGG 
141s4f GTCTGCTCTTCTACAGG   
141s5f GATGGATGGAGGATGC   
141s6r   GTAGAAGAGCAGACCCAACAAT 
141s7r   AACCATAGTTAGTACCTCTGGAAC 
141s8r   GGATCCGAGCCGCGTCTGCAA 
141s9r   TGGTTCCTAGTCGGGTTCGTTAAC 
141s10r   CGACAGAGTATCTGAACATAA 
141s11r   CAGAAATAGTCGCAATGTGCC 
141s12r   TAGCACAGAAGATAATCTCAAGA 
141s13f ATGTCTTAGTGTGGGCACATT   
13int1 CTTTCCGCATCCGATAGCCT GTACCAAAGCCCGTCTAGCA 
13int2 GTAGGGCGGTGACCTTGAAA GTGGATCATTCAGGGGCCAT 
13int3 CAGCCTGTGATCCTCCTAGC CATCCCTTTTGTGTCCGCCA 
13int4 ACACTCAGAACAGAGACGCC GTGCACGACGGGTTATCCTA 
n523int1 GTTCAGACCATCAGGGCTCC GTTCTCGGGTGTTAGGGGTG 
n523int2 TTGCTAACCAGGCGTCATCA GCGCACCACTGAAAACAGAC 
523int3 GTACCAAAGCCCGTCTAGCA CACATGCAGCAGTCCTACCA 
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Name                 forward 5'-3'                  reverse 5'-3' 
523int4 AAAGCCCGTCTAGCAGGGAA CCAGATGCCCCGACTATTCA 
641int1 AGTTCAGATGGTCTGTTGGGTTCT GCGCACCACTGAAAACAGAC 
641int2 AACCTTCAGAGGCGAGGTCT GCCGGTACATGCATACACGT 
641int3 GTACCAAAGCCCGTCTAGCA ATCGGGACCTCAGGTGAGAA 
641int4 GCCGCTAGCTCTACCAGTTC TGAGCTGCCCAAGATACAGC 
n641int2 CTTCAGAGGCGAGGTCTCG   
718int1 TCTTCCTCCTTCCTTCCACCA CCTTACGGCCTGAGAGGACA 
718int2 GACCTCCTTCCTTGTGTCCTC GTGATCCTCCTAGCACGTCTG 
718int3 TAACCTGGAGGAATCCCTAACC GAGGCAGGGACAGTTTGGAG 
718int4 CTGGAGGAATCCCTAACCTC GAGGCAGGGACAGTTTGGAG 
718int5 GGTGGGGCGTTGAAATTGAT TGAGAGGACAGCTGCAAACC 
718int6 TGTGGAGAGAGGAAGGGATTTA 
AAACAGACACTCAGAACAGAGA
C 
718int7 AGACAACAGTACCAAAGCCCG TTGAGAGGCAGGGACAGTTTG 
718int8 GCAGTCCAGATCATGGTACTTAG GGGACAGTTTGGAGAACACA 
1679int1 GTGCTTTTGCGAACAAGGCT TGACCGACAGTAGGAGACCA 
1679int2 AGTGAACAAGGTGCTTTTGCG TGAGAGGACAGCTGCAAACC 
1679int3 AGTACCAAAGCCCGTCTAGC AGCACCTATGCAATGGCTCC 
1679int4 TCCTGTTACTCACAGTTGGGC TGCAATGGCTCCAGATGCTAA 
13104int1 AGTTTCTTGTGTGTCGGTTGC GCCTGTGATCCTCCTAGCAC 
13104int2 TGCATACCAGATTCAGGCAAGT AGCAGCCTGTGATCCTCCTA 
13104int3 AAGGGTGGTTTGAGGGATGG AGGGGCAAGGTAAGCTTTTCA 
13104int4 GTACCAAAGCCCGTCTAGCA CTTTGGCAAGGGGCAAGGTA 
n13104int2 TCTTGTGTGTCGGTTGCCAT   
13104s5f GCCGCTAGCTCTACCAGTTC   
13104s6f ACTCACAGTTGGGCCATGTA   
13104s7r   GCTTCTGACCAACTGACTCTAA 
13104s8r   CCAGGGTTGGTTATTTGTGAGA 
210int1 TCTCATGCCCAATGGTTTGC CAACAGTACCAAAGCCCGTC 
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Name                 forward 5'-3'                  reverse 5'-3' 
210int2 CCTCTGTGGGGACAATGGAT TCCTGTTACTCACAGTTGGGC 
210int3 GGACAGCTGCAAACCGAAAG ACCCTCCCTTTAGGAAAAACCC 
210int4 TAGCACGTCTGCTGATCACAGTC CCATTCCCTCCAGAAGCCA 
210int5 CCAGCCTAATTCCCATCCCTC AGACAACAGTACCAAAGCCCG 
210int6 CAGGTATCAGCATCTCCTCCTA AGGAGGACTATTAAGGGT 
210int7 GTGATCCTCCTAGCACGTCTG GTCTTGGGCTTCCATGTGGATT 
210int8 AACAGACACTCAGAACAGAGAC TGGGCTTCCATGTGGATTT 
X14int1 CATGTCTGTCCTGCCTCTGG GTACCAAAGCCCGTCTAGCA 
X14int2 ACCAGTAAGAGAAGGTCGATGT AACAGTACCAAAGCCCGTCT 
X14int3 TGAGAGGACAGCTGCAAACC GGGCGTGTTCAAAAGAGTGC 
X14int4f GCCTGTGATCCTCCTAGCAC CCTCGCTGGTCAATTGCTTG 
4135int1 ACTGGCTCTGAACCGTTTGG CACTCAGAACAGAGACGCCG 
4135int2 TTTGGGGCTGAGGCTGTTAGA CGGCCGGTACATGCATACAC 
4135int3 AACAGTACCAAAGCCCGTCT CGTATCTGTCTGTGTCCGGG 
4135int4 CAACAGGTCTCTTTGGTTGGC TCCCATTTCTGGCAAGAGCC 
120int1 GTACTGGGCTTTTGCATCGC GCCTGTGATCCTCCTAGCAC 
120int2 CTCTTGCAGGTAGCCTTCGC CGGTCCTCTGACCGACAGTA 
120int3 TACTCACAGTTGGGCCATGT GGGCTGGTAAGGAAAGCAAAC 
120int4 AGACAACAGTACCAAAGCCCG TTAAGCAGGGCTGGTAAGGAA 
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1.6.  Primary cells, bacterial strains and plasmid vectors 
 
 
 
 Description/ Manufacturer 
Pig primary 
kidney cell line 
3990 GalKO+/-,CD46, INS-LEA 
  1476 INS-LEA 
  4504 GalKO+/-, CD46, hTM 
  4686 GalKO-/-, CD46 
  PKCm                    Wild type Landrace pig  
Bacterial strain  Top 10 Invitrogen, Karlsruhe 
Plasmid       gRNA vectors             Thermo Scientific, Schwerte 
         Cas9 vector Addgene, USA 
 
 
 
1.7.  Chemicals, enzymes and other reagents 
 
Acetic Acid (glacial) (HOAc) Roth, Karlsruhe 
Agarose Universal Bio&Sell, Nürnberg 
Ampicillin Roth, Karlsruhe 
BigDye® Terminator v3.1 Applied Biosystems, Weiterstadt 
β-mercaptoethanol  Sigma, Steinheim 
Bromophenolblue Roth, Karlsruhe 
Chloroform (Tricholomethane) Roth, Karlsruhe 
CollagenR Serva, Heidelberg 
DifcoTM Trypsin 250 BD,USA 
Dimethyl sulfoxide (DMSO) Sigma, Steinheim 
Dithiothreitol (DTT) Sigma, Steinheim 
DNA loading dye (6x) Thermo Scientific, Schwerte 
Dulbecco modified Eagle medium (DMEM) Gibco, Darmstadt 
dNTPs (dATP, dCTP, dGTP, dTTP) Thermo Scientific, Schwerte 
EDTA (Ethylenediaminetetraacetic acid) Roth, Karlsruhe  
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Ethanol (EtOH) Roth, Karlsruhe 
GelRedTM Nucleic Acid Gel Stain Linaris, Dossenheim 
Gene Ruler™ 1 kb Thermo Scientific, Schwerte 
Glutamax Gibco Thermo Scientific, Schwerte 
Glycerin (Glycerol) Roth, Karlsruhe 
Fetal calf serum (FCS) Invitrogen, Karlsruhe 
Herculase II Fusion DNA Polymerase Agilant technologies, USA 
Herculase II 5x reaction buffer Agilant technologies, USA 
Hydrochloric acid, 37 % (HCL) Roth, Karlsruhe 
Isoamylalcohol Roth, Karlsruhe 
Isopropanol Roth, Karlsruhe 
LB-Agar Roth, Karlsruhe 
LB-Medium Roth, Karlsruhe 
Magnesium chloride (MgCl2) Fluka Chemie, Switzerland 
Non-essential amino acids (100x) Gibco, Darmstadt 
Polyethylenglycol (PEG) 8000 Roth, Karlsruhe 
Phenol Roth, Karlsruhe 
Proteinase K Roth, Karlsruhe 
Potassium acetate (KOAc) Roth, Karlsruhe 
Potassium chloride (KCl) Sigma, Steinheim 
di-Potassiumhydrogenphosphate (KH2PO4) Roth, Karlsruhe 
Ribonuclease A Thermo Scientific, Schwerte 
SOB-Medium Roth, Karlsruhe 
Sodium acetate Sigma, Steinheim 
Sodium dodecyl sulfate (SDS) Serva Electrophoresis, Heidelberg 
Sodium chloride (NaCl) Sigma, Steinheim 
Sodiumdihydrogenphosphate (Na2HPO4) Sigma, Steinheim 
Sodium hydroxide (NaOH) Roth, Karlsruhe  
Sodium Pyruvate  Invitrogen, Karlsruhe 
T4 DNA ligase and buffer (10x) Thermo Scientific, Schwerte 
Tris-(hydroxymethyl)-aminomethane (TRIS) Roth, Karlsruhe 
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1.8.  Buffers and solutions for molecular genetic protocols 
All buffers and solution were prepared with water deionised in a Millipore machine 
(EASYpure® II, pure aqua) called aqua bidest. 
                             Name                                       Components 
DNA molecular weight standard 100 μL Gene RulerTM 1 kb 
  100 μL 6x DNA loading dye 
  400 μL aqua bidest. 
  Aliquoted and stored at -20°C 
DNA loading buffer (10×) 10 % glycerol in aqua bidest. 
  1 spatula tip of Bromophenol Blue 
  0.5 M NaOH added till color turns blue 
  Aliquoted and stored at 4°C 
                      dNTPs mixture                      2 mM dATP, dCTP, dGTP, dTTP 
  Dissolved in aqua bidest 
  Aliquoted and stored at -20°C 
TAE buffer (50×) (2l) 2 M Tris (484 g) 
  200 mL 0.5 M EDTA (pH 8.0) 
  114 mL glacial acetic acid 
  Brought to 2 L volume with aqua bidest. 
  Filtrated and autovlaved  
  Before use diluted to 1X concentration 
Sequencing buffer (5×) 17.5 mL 1 M Tris/HCl (pH 9.0) 
  125 μL 1 M MgCl2 
  50 mL aqua bidest. 
  Aliquoted and stored at -20°C 
PK buffer (10x) 200 mM Tris 
  1 M NaCl 
  40 mM EDTA 
  Stored at room temperature 
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                             Name                                       Components 
PEG-MgCl2 40 % (w/v) PEG 8000 
  30 mM MgCl2 
  Stored at room temperature 
Phenol-Chloroform-isoamylalcohol  25 mL Phenol 
 (PCiA) 24 mL Chloroform 
  1 mL Isoamylalcohol 
T-buffer 10 mM Tris 
  HCl added till pH 8.0 
Plasmid A solution 50 mM glucose 
  25 mM Tris/HCl pH 8.0 
  10 mM EDTA/NaOH pH 8.0 
Plasmid B solution 0.1 M NaOH 
  0.5 % (w/v) SDS 
  Freshly prepared 
Plasmid C solution 3 M KOAc 
  9 M HOAc till pH 4.8  
  Autoclaved 
STE 10 mM Tris/HCl pH 8.0 
  100 mM NaCl 
  1 mM EDTA/NaOH pH 8.0 
 
1.9.  Media and solutions for cell culture protocols 
                             Name                                       Components 
Cell culture medium DMEM with Glutamax  
  1 % Non-essential amino acids (100 %) 
  15 % Fetal calf serum (FCS) 
  0.1 mM β-mercaptoethanol 
Stop medium DMEM with Glutamax 
  10 %  FCS 
 
 
 
 
III. Materials and Methods 35 
 
 
 
                             Name                                       Components 
Cryo medium 10 % DMSO  
  90 % FCS 
  Freshly prepared 
PBS without Ca2+/Mg2+ 8 g NaCl 
  0.2 g KCl  
  0.2 g KH2PO4 
  2.14 g NaH2PO4 · H2O 
  1000 mL aqua bidest. 
Trypsin/EDTA PBS  without Ca
2+/Mg2+ 
  0.5 % Trypsin 
  0.04 % EDTA 
 
2. Methods 
Molecular genetics and cell culture methods as well as bioinformatics approaches were 
used for detection of PERV C loci in the genome of 4 chosen animals, characterization 
of PERV C integration sites in these cells, PERV C screening in our xeno herd, for the 
excision of PERV C from the genome of the selected animal through engineered 
CRISPR/Cas9 system and for following analysis of the produced single cell clones. 
2.1.  PERV diversity by Targeted Locus Amplification  
PERV C loci detection was performed by Cergentis Ltd, Utrecht, Netherlands 
(https://www.cergentis.com/) through TLA sequencing described in de Vree et al. Nat. 
Biotechnol. 2014. The primary kidney cells used for the analysis were isolated from 
the animals 3990 (GalKO+/-, CD46, INS-LEA), 1476 (INS-LEA), 4504 (GalKO+/-, 
CD46, hTM) and 4686 (GalKO-/-, CD46). For the screening 4 probes were designed 
on a non-homologous region of PERV C env gene by Dr. Nikolai Klymiuk.  
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2.2.  Chromosomal integration sites characterization of PERV C loci 
and primer designing for their screening               
The chromosomal integration site localization of all PERV C loci was performed using 
the bioinformatics tool Ensemble starting from the known flanking regions of every 
PERV C found. Once the localization sites were found, the relative sequences were 
used in the repeat masker tool to find in this regions repetitive segments in the entire 
pig’s genome in order to design primer pairs with specificity for the region of interest. 
To design specific primer pairs, tools like Primer Blast, PrimerQuest and Tm calculator 
were used. 
2.3.  Genomic DNA isolation from primary kidney cells 
In order to set up optimal conditions for new screening PCRs and to characterize PERV 
C integration sites, genomic DNA was isolated from the primary kidney cells of the 
animals 3990, 4686, 4504, 1476 and as control from a primary porcine cell line 
“Kidney M” isolated from the kidney of a 3 months old male Landrace pig. The 
isolation, cultivation, freezing and thawing protocols for these cells have been 
established and performed from Dr. Annegret Wünsch and Eva Maria Jemiller 
according to RICHTER et al. (2012). The DNA isolation was performed using the 
Easy-DNA™ Kit purchased from Invitrogen, Karlsruhe according to manufacturer’s 
instructions and precisely the protocol nr. 3. The obtained DNA was dissolved in 55 µL 
of T-buffer and 1 µL of it was used to determine the concentration and purity by 
Biochrom™ SimpliNano Spektrometer. From each DNA than was made an aliquot of 
100 ng/ µL which was used as template for the following analysis.  
2.4.  Genomic DNA isolation from pig tails 
To screen the animals of our xeno herd for all PERV C integration sites found by TLA 
analysis genomic DNA from each pig was isolated with two methods. In the first 
method DNA was isolated from 2 tail’s slices (1 mm each) using the Nexttec™ 
Genomic DNA Isolation Kit purchased from nexttec GmbH, Leverkusen according to 
manufacturer’s instructions. This DNA was used directly as template for PCR.  In the 
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second method, which demonstrated to be a better option, the DNA was isolated from 
pig’s tail piece of 1 cm³ using the protocol nr. 8 of the Easy-DNA™ Kit mentioned 
above. After that, the DNA concentration was measured and diluted to 100 ng/µL as 
reported in 2.3. 
2.5.  Polymerase chain reaction (PCR)  
PCR protocols used for multiple purposes in this work, have in common the 
amplification of a determined genomic part using primer pairs specific and 
complementary to the extremities of the sequence of interest. To identify the best 
primer pairs and the optimal working conditions useful for the screening of every 
PERV C locus in the different chromosomes all the designed primer pairs were tested 
with different working conditions like for example changing the annealing temperature 
and/or the elongation time and/or primer concentration. All the master mix 
components were mixed on ice to have a final concentration of 25 µL and the reaction 
was performed in PCR cycler within 0.2 mL PCR tubes. For every PCR run was used 
as template the DNA previously isolated and aqua bidest. as contamination control. To 
sequence the PCR products if further required the PCR experiments for every sample 
were performed in double. The master mix components as well as the PCR conditions 
as showed below at test starting point were the same for every designed primer pair 
and changed depending on the performance of the PCR to find the optimal working 
requisite.  
Table 1: PCR components                               
Herculase II 5x reaction buffer 5.0 μL 
dNTPs (2 mM) 2.5 μL 
Primer forward (10 μM) 0.4 μL 
Primer reverse (10 μM) 0.4 μL 
Herculase II DNA Polymerase 0.2 μL 
aqua bidest.  15.5 μL 
Template  1.0 μL 
Total volume  25 μL 
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2.6.  Agarose gel electrophoresis 
In order to detect the amplified DNA, the PCR samples were used to run on an 1% 
agarose gel electrophoresis. Universal Agarose at concentration 1 g/100 mL was 
dissolved in 1x TAE buffer by heating in the microwave and after cooling down till 
60°C was added GelRed™ Nucleic Acid Gel Stain (2 μL/100 mL). The solution was 
then poured in an electrophoresis chamber and after its polymerization the chamber 
was filled with 1x TAE buffer. Each PCR sample as well as 6 μL of 1 kb Gene Ruler™ 
DNA molecular weight standard useful for the DNA size estimation was mixed with 
2.5 μL 10x DNA loading buffer and loaded into single gel slots. In order to separate 
the DNA fragments depending on the size a 130 Volt electric field was applied to the 
chamber. At the running end the gel was put in a Gel documentation system and the 
DNA bands were visualized by UV light. In this case too, in order to sequence the PCR 
products if further required the DNA bands were excised and used to obtain the DNA 
elution. 
2.7.  DNA elution 
The DNA was eluted directly from the PCR samples or from the gel containing the 
band of our interest. In the first case, one reaction was used for agarose gel 
electrophoresis and the reaction copy was used as sample for the NucleoSpin®Gel and 
PCR Clean-up kit following manufacturer’s PCR clean-up protocol in order to obtain 
the eluted DNA. In the second case, the excised band was used to obtain the DNA 
using the protocol Isolation of DNA from agarose gels of Double Pure Kombi Kit 
Table 2: PCR cycler program  
  
First denaturation 95 °C  5 min  
Denaturation 95 °C  30 s   
Annealing 58 °C  30 s  x 35 
Elongation 72 °C  30 s   
Final elongation 72 °C  10 min  
Termination   4 °C  15 min  
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according to manufacturer’s instructions. To verify if DNA was really eluted 2 μL of 
the obtained solution was mixed with 2 μL of 10x DNA loading buffer and with 15 μL 
of aqua bidest. and was loaded in a 1 % agarose gel together with 6 μL of 1 kb Gene 
Ruler™ DNA molecular weight standard. The eluted DNA was further used as sample 
for the following sequencing method. 
2.8.  Sanger sequencing  
The Sanger approach was used to characterize at nucleotide base level all the eleven 
PERV C integration sites found in the 4 before mentioned primary cells. This 
sequencing method (SANGER et al., 1977) permits to know the exact nucleotide 
sequence of an amplified DNA fragment based on the incorporation of labelled 
dideoxynucleotides (ddNTPs) which induce termination of the DNA chain extension. 
In each 0.2 mL reaction tube a target DNA fragment is sequenced with one primer so 
that a DNA fragment can be sequenced with different primer pairs in different 
reactions. The PCR products were sequenced with the own forward and reverse 
primers as well as when necessary with primers pairing internal sequences of the target 
DNA. The master mix components and the sequencing reaction cycler protocol are 
shown below (Table 3,4). At the end of the running program the sequencing products 
were purified through ethanol precipitation. To the sequencing reaction was added first 
2.5 µL of 125 mM EDTA and then 30 µL of precooled 100 % EtOH. All the volume 
was then transferred into a 1.5 mL tube and incubated on ice for 15 min. After 13.000 
rpm centrifugation at 4°C for 30 min the supernatant was removed and the pellet was 
washed overnight with 50 µL of 70 % EtOH. The next day after 2.5 min centrifugation 
at 13.000 rpm and after supernatant removing the pellet was air dried and dissolved in 
30 µL of aqua bidest. The purified samples were transferred to a sequencing plate 
provided from Genome Analysis Center, Helmholtzzentrum Munich which performed 
the reading of the Sanger sequencing reaction results. The analysis of the nucleotide 
sequences was made using bioinformatics tools like FinchTV Version 1.3.1 and Bio 
Edit Sequence Alignment Editor.  
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Table 3: Sequencing reaction components  
5x sequencing buffer 4 μL 
BigDye 1 μL 
Primer (10 μM) 1 μL 
aqua bidest. 2 μL 
DNA template 2 μL 
  
 
Table 4: Sequencing cycler program  
  
First denaturation 95 °C   1 min  
Denaturation 95 °C   5 sec   
Annealing 52 °C   10 sec  x 40 
Elongation 60 °C    4 min   
Termination   4 °C   15 min   
 
2.9. gRNA designing and sequence proofing  
After the integration site characterization, gRNAs enclosing PERV C locus were 
designed using the chop chop software. The construct expressing the designed gRNA 
fused with tracrRNA and the construct expressing Cas9 was purchased from Thermo 
Scientific, Schwerte and delivered in MALI vector according to (MALI et al., 2013). 
In order to proof the commissioned gRNA sequences and to prepare stock, the gRNA 
vectors were transformed in TOP 10 E.coli cells and sequenced after plasmid 
preparation of the bacterial cultures. 
2.10. Heat Shock Transformation 
In order to perform the transformation of TOP 10 cells every 5 µg lyophilized gRNA 
vector was dissolved in 7 µL in endofree T- buffer. From this solution 1 µL was diluted 
in 999 µL of T-buffer and 1 µL of it was used for the transformation. The -80° C 
conserved competent cells were thawed carefully on ice and 1 µL of gRNA vector 
solution was added and mixed gently avoiding re-pipeting. After incubation on ice for 
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30 min the cells were put in a 42° C water bath for 45 seconds and then again on ice 
for 2 min. To every reaction tube 1 mL of SOB medium was added under sterile 
laminar flow and afterwards they were incubated for 45 min at 37° C. During 
incubation time the LB agar plates added with Ampicillin (50 µg/mL) were signed up 
and put in the same incubator to equilibrate. After recovering the cells were centrifuged 
at 4.4 rpm for 4 min and 800 µL of the supernatant were thrown away. The pellet was 
resuspended in the remaining 200 µL, plated in the LB agar-Ampicillin Petri dishes 
and incubated overnight at 37° C. Only the cells that have integrated the plasmid will 
be resistant to Ampicillin, grow in colony and be ready for further analysis. 
2.11. Glycerol stock and plasmid preparation 
The next day single colonies from agar plates were inoculated into sterile culture tubes 
containing LB medium-Ampicillin and incubated overnight at 37° C in a shaking 
incubator. Some of the overnight grown cultures were used for the glycerol stocks 
preparation consisting in a mixture of 300 µL of glycerol 60 % and 900 µL of bacterial 
culture which were then stored at -80° C. The other tubes were centrifuged for 10 min 
at 3000 rpm and the supernatant was discarded. The pellets were resuspended with 750 
µL STE buffer and transferred into 1.5 mL tubes before to be centrifuged for 5 min at 
700 rpm. After removing the supernatant, the obtained pellets were frozen for 15 min 
at -20° C and were resuspended by pipetting in 200 µL Plasmid A buffer. 
Consecutively 400 µL of Plasmid B buffer was added and the samples were mixed by 
hand, inverting the tubes till a precipitate was observed. After incubation on ice for 5 
min 300 µL Plasmid C buffer was added, gently mixed and then again incubated on 
ice for 5 min. After centrifugation at 13.200 rpm for 10 min, the supernatants were 
transferred in new signed 1.5 mL tubes containing each 4 µL of RNase A and incubated 
at 37° C for at least 45 min. In order to extract the plasmid DNA from the solution 
containing proteins and other cellular residues, 300 µL of PCiA was added in all the 
tubes which were then shaken for 1 min and centrifuged at 13.200 rpm form 2.5 min 
in order to separate the two phases. The aqueous phase was transferred into a new tube 
and after adding 650 µL isopropanol the samples were inverted more time, centrifuged 
at 13.200 rpm for 10 min and the supernatant was discarded. The DNA pellet was 
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washed with 700 µL of 70 % EtOH, centrifuged again at 13.200 rpm for 2.5 min and 
after discarding the supernatant was air dried for 6 min and resolved in 55 µL of T-
buffer. After resolution the DNA concentration was measured. 
2.12. PEG precipitation 
In order to be sequenced the DNA need to became further purified by PEG 
precipitation. Therefore, 20 µL of the above plasmid DNA was mixed with 20 µL of 
aqua bidest. and 20 µL of PEG- MgCl2 and the whole was incubated for 10 min at 
room temperature and then centrifuged at 13.200 rpm for 20 min. After discarding the 
supernatant, the DNA pellet was washed overnight with 300 µL of 70 % EtOH and 
centrifuged for 2.5 min at 13.200 rpm the next day. The supernatant was removed, the 
pellet was air dried for 6 min and then resolved in 20 µL of T-buffer. The final 
concentration was measured again using Biochrom™ SimpliNano Spektrometer and 
the samples were diluted to a concentration of 30 ng/µL with T-buffer and directly 
used as template for the sequencing reaction. In order to verify the exact sequence of 
gRNAs the samples were sequenced like described in 2.8 with the control gRNA 
primer (CRP) forward and reverse. 
3. Targeted excision of PERV C loci and generation and screening of 
single cell clones 
3.1.  Transfection  
In order to excise PERV C locus, transfection on 3990 cells was performed with 2 
gRNAs and Cas9. One transfection was performed with 2.5 µL of gRNA 141C51, 2.5 
µL of gRNAC31 and 1 µL of Cas9 each with a concentration of 300 ng/µL. The other 
transfection combination consisted in 2.5 µL of gRNA 141C52, 2.5 µL of gRNAC31 
and 1 µL of Cas9. Transfection on the 3990 cells and their freezing were performed 
by Dr. Annegret Wünsch and Eva Maria Jemiller according to (RICHTER et al., 2013).                       
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3.2.  Single cell clones generation 
To verify the occurred excision of PERV C locus by CRISPR/Cas9 single cells clones 
were produced from the cells previously transfected. At first, the cells were thawed and 
diluted in 10 mL DMEM added of fetal calf serum (FCS) in a quantity of 10 % to obtain 
an amount of 150 cells pro 96 well half area plate. The calculated cells amount then was 
added to the cell culture medium and in order to have 1 or 2 cells per well 50 µL of 
this solution was seeded on each well of the cell culture plate which was previously 
coated with collagen and put in cell CO2 incubator at 37°C.  The cell culture medium 
was exchanged every 72 hours and every time plates were scanned for single cell clones 
using Cellavista (Synentec) which take images of each well useful to document the growth 
of the single cell clones. The obtained single cell clones once being at 80 % of confluence 
were washed with 100 µL of PBS and detached using 30 µL of Trypsin/EDTA solution 
and incubated at 37° C for 5 min. After stopping the reaction with 170 µL of cell 
culture medium added with 15 % of FCS, the cell clones of one well were split on two 
different wells and cultivated changing medium every 72 hour till the full confluence 
was achieved. Cells of one well were then cryo preserved as backup adding 170 µL of 
previously cooled FCS with 10 % DMSO and transferring all in cryo tubes wich were 
immediately put in –80° C. The cells of the other well were used for DNA isolation 
useful to screen if the excision took place and therefore 170 µL of stop medium was 
added and the whole amount was transferred in 1.5 mL tube. The tubes of more single 
cell clones were then centrifuged for 5 min at 400 x g, the supernatant thrown away 
and the tubes containing the cell pellet were frozen at -80° C ready for the DNA 
isolation. 
3.3.  Single cell clones DNA isolation by high salt precipitation 
At first the cells were resuspended in 100 µL of PK buffer and then 10 µL of SDS (10 
%) and 4.4 µL of 1M DTT was added before mixing by pipetting. After incubation at 
60°C for 1 hour were added 2 µL of proteinase K (20 mg/mL) and again the samples 
were further incubated like above. At the end of incubation time 30 µL of NaCl (4.5 
M) were added and after pipetting and incubation for 10 min on ice the tubes were 
centrifuged for 20 min at 13.200 rpm. The supernatant was transferred to a new 
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reaction tube, 110 µL of isopropanol were added and the samples were shaken 
carefully to precipitate the DNA. The tubes were then centrifuged again for 20 min at 
13.200 rpm, the supernatant was discarded carefully and 500 µL of 70 % EtOH were 
added before incubating at 4°C for the whole night. The next day the samples were 
centrifuged for 2.5 min at 13.200 rpm, the supernatant thrown away and the pellets 
were air dried for 6 min. In every tube then were added 45 µL of T buffer and to 
dissolve the DNA the reaction tubes were incubated for 1 hour at 60°C. The isolated 
DNA was then stored at 4°C. 
3.4.  Screening of single cell clones   
To verify in which clones the provirus was successfully excised the isolated DNA of 
the clones was used as template for PCR using different primer pairs such locating on 
the flanking regions outside the targeted locus. The clones that lack the provirus were 
further tested either by sequencing as described on paragraph 2.8. or by PCR with 
primer pair specific for env C and with primer pairs specific for the LTRs. The PCR 
reactions were performed as described in paragraph 2.5.   
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IV. Results 
1. PERV integration sites 
To have an overview of the distribution of PERV in porcine species, at first all PERV 
integration sites were identified in the reference genome and in the 4 chosen animals 
of our herd. The flanking regions of every PERV C locus were then used to 
characterize the chromosomal location of proviruses. 
1.1.  PERV in Tabasco reference genome  
The Tabasco reference genome (11.1 version) was examined for PERV A, B and C 
proviruses using sequences from the most divergent part of the env gene. In addition, 
a sequence from the highly conserved gag gene was used for screening the reference 
genome. Sequences from the env of AJ293656, AJ293657 and AF038600 were used 
as probes for PERV A, B and C, respectively. The sequence of gag from AJ293656 
was used as a probe for the highly conserved gag gene. All positions of PERV and the 
percentage of homology to the reference PERV are reported in the Figure 1.  In total 
56 proviruses were identified in the pig reference genome; 15 of them were only 
identified by the gag gene and, thus, likely lack an intact env. 7 of the proviruses 
appeared to have an intact ORF in all 3 retroviral genes. The proposed age of the 
proviruses is diverse, indicated by difference in the LTRs and ranging from 19 
mutations per 590 nucleotides in a PERV at in chromosome Y:20.19Mb to 0 per 631 
nucleotides in a PERV at chromosome 15:110.96Mb. Interestingly, no PERV C was 
identified in the pig reference genome. 
Further, all identified PERV sequences then were examined for their internal structure, 
regarding LTR, gag, pol and env. Not all PERV conserve their intact sequence and a 
significant proportion has larger deletions in the pol and env gene or on their terminal 
ends (Fig. 2). Very interestingly a group of 12 proviruses contain an identical gap in 
the env gene, and some of them have consistent additional gaps in the pol and gag 
genes. The gap in the env gene prevent speculation about the tropism of this group of 
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PERV. How this group of proviruses has expanded in the pig genome without a 
functional env remains unclear. 
 
Figure 1: Proviruses from Tabasco reference genome.  
Matches identified by BLAST in the Ensemble pig reference genome are characterized 
by the length of the match and the homology in the matching region. Proviruses are 
defined by the chromosomal position and their relative orientation. For each provirus, 
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the open reading frame of the gag, pol and env genes was examined and proviruses 
with intact ORF in all 3 genes are indicated in bold. If available, the sequences of the 
5` LTR and the 3’ LTR were compared and the number of mismatches is shown. If one 
or both LTR were not completely abundant, differences were not determined (nd). 
Proviruses with more than 95% env A homology are indicated in green; proviruses 
with more than 95% env B homology are indicated in magenta and the proviruses that 
have a homology with env of PERV A, B or C less than 95 % are indicated in gray. 
1.2.  PERV in our herd –TLA sequencing analysis 
TLA sequencing was performed by Cergentis Ltd (Utrecht, Netherlands) in primary 
cells obtained from 4 genetically modified animals from our xenotransplantation 
breeding herd. Specifically, the animal 3990 was GalKO+/-, CD46, INS-LEA; pig 
1476 was INS-LEA; pig 4504 was GalKO+/-, CD46, hTM and the animal 4686 was 
GalKO-/-, CD46. For the screening 2 sets of primers for env and 1 primer pair for each 
gag and pro/pol were used to differentiate PERV C subtype from A and B. Flanking 
sequences were then identified in the pig reference genome version 10.2. available in 
December 2016. Totally, 11 PERV C loci were found (Fig. 3).  Importantly, none of 
the animals were found to be PERV C free, with PERV load ranging from 1 to 8. The 
animals 3990 and 4686 comprise only one PERV C at chr1:41Mb and at chr7:18Mb, 
respectively. Pig 1476 has 5 integration sites at chr1:20Mb, chr1:41Mb, chr4:135Mb, 
chr5:23Mb and at chr13:104Mb while animal 4504 is the animal with most PERV C 
proviruses integrated in its genome located at chr1:20Mb, chr1:3Mb, chr1:41Mb, 
chr2:110Mb, chr6:41Mb, chr7:18Mb, chr16:79Mb and at chrX:14Mb.  
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Figure 2: Internal structure of PERVs in Tabasco reference genome. 
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Figure 3: PERV C in our breeding herd. Genomic matches of provirus-flanking 
region have been identified with 4 independent primer pairs by TLA sequencing. Only 
proviruses with consistent matching of all 4 primer pairs were designated as PERV C. 
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1.3.  Chromosomal integration sites characterization of PERV C loci 
Next goal was the precise localization of PERV C proviruses with respect to porcine 
genes. The flanking region sequences from TLA sequencing analysis of all PERV C 
sites were used to localize the integration sites with respect to annotated genes and to 
establish specific PCR for each provirus. The screening of provirus integration sites 
was repeated once the significantly improved reference genome 11.1 was available 
(Fig. 4 and 5), but the nomenclature of integration sites was maintained as initially 
defined upon 10.2 reference genome. In 7 of the 11 PERV C loci detected, the 
integration events have been occurred in intergenic regions of the porcine genome 
although (Fig. 4).  
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Figure 4: Localization and direction of PERV C loci in intergenic regions. The 
flanking regions of the proviruses identified by TLA-sequencing were used to identify 
the integration site. The direction of the provirus is indicated by an arrow. An overview 
of the proviral integration site is shown in the lower panel whereas the zoom-in in the 
upper panel indicates the position of the integration site and the position of the nearby 
genes in more detail. Gene annotations are indicated by the Ensemble style.  
 
 
In the 4 remaining PERV C loci the provirus is integrated within intronic regions of 
annotated genes (Fig. 5). 
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Figure 5: Localization and direction of PERV C loci within to annotated genes. The 
elements are given as in the Fig. 4 and exons of porcine genes are confirmed by their 
homologies to the orthologous cDNAs from human and/or cattle. 
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2. Screening for identified PERV C loci in our animals 
Next goal was the establishing of reliable screening tools for each of the identified 
PERV C proviruses in our herd. Based on the integration sites of the 11 PERV C loci 
defined in paragraph 1.3, primer pairs were designed to establish specific PCRs for 
both sides of the PERV C loci. The optimized primer pairs were used also to confirm 
the LTR on the 5’ and 3’ end of all PERV C for a precise determination of proviruses 
integration time point, based on molecular clock hypothesis (TONJES & NIEBERT, 
2003).  
2.1.  Optimizing PCRs and LTRs characterization 
For each of the 11 PERV C loci 2 primer pairs on the 5’ end and 2 primer pairs on the 
3’ end were designed and tested under different conditions. The initial annealing 
temperature was 58°C which was then modified during the optimization process, 
together with other PCR conditions such as elongation time, annealing time, MgCl2 
and primer pairs concentration. For some of PERV C loci it was necessary to design 
and optimize new primers. The optimal annealing temperature for the most of the 
primer pairs was 60°C, whereas the elongation time was substantially different for 
most of the optimized PCR. For every locus the best PCR for the detection of PERV 
C loci in our herd are reported in the figures 6. The sequences of 5’ and 3’ the LTRs 
were then compared to identify point mutations to determine the age of the provirus. 
Surprisingly, no difference was found between any of the LTR pairs and the LTR 
between the proviruses differed by 1 nucleotide at most. The PERV C LTR sequences 
were also (almost) identical to the LTRs in AF038600 which has been used as the 
PERV C reference. The pattern suggests a very recent integration into the pig genome. 
Based on general consideration there is assumed that the provirus integration occurred 
not more than 100.000-400.000 years ago (TONJES & NIEBERT, 2003). 
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Figure 6: Site specific PCR for each PERV C locus. Primer names, their position as  
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well as the optimal annealing and elongation conditions indicated. A representative 
PCR figure is given and the Sanger sequencing electropherograms show the transition 
from the genome into the provirus. For chr1:41Mb an additional PCR was optimized 
for detecting alleles that do not contain the (right panel). 
2.2.  Xeno herd screening 
The established PERV C loci PCR allowed to screen our existing xeno donor herd for 
the integration of the provirus. The screening for PERV integration sites is used in our 
lab as routine genotyping procedure for new litters (Tab. 5) in addition to the 
genotyping for genetic modifications. Up to now 278 animals with different transgenic 
background were screened initially by myself and meanwhile by lab-technicians. 32 
of these animals did not have a PERV C integration in the 11 tested loci and in present 
xeno herd (20 animals) 4 of the animals are proven as PERV C free. The other 16 
animals have PERV C in the chr1:20Mb, chr1:3Mb, chr1:41Mb, chr4:135Mb, 
chr7:18Mb, chr16:79Mb and in the chrX:14Mb. Thus, 4 of the initially identified 
proviruses, namely in chr2:10Mb, chr5:23Mb, chr6:41Mb, chr13:104Mb have been 
sustainably extincted from our herd. 
 
Table 5: PERV C loci screening in our xeno herd. Representative screening for PERV 
C loci in our xenotransplantation herd. Animal lacking any provirus integration are 
shown in orange. Their genotype is indicated in the right-most column (GTKO= 
homozygous KO of the GGTA1 locus; bLEA= homozygous knock in for bLEA locus; 
hTBM= homoozygous knock in for TBM locus). 
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2.3.  Side-finding: A new PERV-subtype in PERV C-free animal 
Animals that were negative for any of the 11 characterized PERV C proviruses were 
tested further for the abundance of unknown PERV C loci. For this we established 
PCR specific for the env C gene, independent of the integration site. Interestingly, 
PERV C negative animals still revealed a PCR band albeit at a much lower intensity. 
Therefore, the PCR bands were excised and the DNA was sequenced. The obtained 
sequences were compared to the PERV A, B and C env reference sequences (Fig. 7). 
The sequences were highly homologous to A, B and C, but they did not fully correlate 
to any of the proviral subfamilies. Instead the sequences were (almost) identical to the 
Gene Bank annotations AF402663 and DQ996276 which have been characterized as 
a new variant of PERV C (HECTOR et al., 2007). The nucleotide sequence defines an 
amino acid sequence that is different from the protein sequences of PERV A, B and C. 
If this resembles a new tropism of PERV remain elusive as well as if this not yet 
described retrovirus is endogenous or represent an active provirus.  
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Figure 7: Sequencing of env C PCR products. The sequences obtained are compared 
with the 3 subtypes of PERV and the Gene Bank annotation AF402663 . The different 
sequence starts at the 256bp position and end in the position 361bp. 
3. PERV C free animals by deleting a selected provirus 
Due to the specific pattern of PERV C integration sites in each animal, selective 
breeding is a promising way to remove PERV C from donor animals for 
xenotransplantation. On the other hand, it is definitely a time consuming way, so 
sometimes it might be more efficient to excise PERV C from the genome of a precious 
animal. Therefore, the possibility to excise single chr1:41Mb provirus from a single 
individual (3990) representing the GTKO, hCD46, bLEA was examined in more 
detail. To achieve this goal, the chr1:41Mb site was characterized in detail, a 
CRISPR/Cas mediated gene editing approach was designed to excise this specific 
provirus. 
3.1.  Characterization of the chr1:41Mb integration site 
First, the zygosity of the chr1:41Mb was determined in animal 3990. For this we used 
the above described primer pairs 1.41exc2, 1:41up2, 1:41int3 to produce PCR products 
and perform Sanger sequencing (Fig. 8).  Importantly, PERV C is integrated in only 
one chromosome. Therefore, in the animal 3990 discrimination of the PERV 
containing and PERV lacking alleles through polymorphisms is important for 
designing sufficient gRNA for excision of the provirus as well as for screening cell 
clones.  
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Figure 8: Amplifying and sequencing primers and their position. All primers for 
characterizing the alleles with or without PERV C are indicated. 
 
The allele without PERV C revealed 17 different polymorphisms which spread over 
2kb when compared with the reference genome at chr1:41Mb (Fig. 9).  
 
 
Figure 9: Polymorphisms of the allele without provirus integration in the 3990 
animal.  
 
 
 
 
IV. Results 62 
 
 
 
Similarly, the allele containing PERV C was sequenced in animal 3990 and the pigs 
4504 and 1476 which contain this specific provirus as well. Overall the PERV-lacking 
and the PERV-containing alleles in pig 3990 differ by 13 polymorphic sites in the 
upstream region of the provirus and further 13 sites in the downstream region of the 
PERV (Fig. 10). 
 
 
Figure 10: Polymorphisms of the alleles with provirus integration. a) PCR products 
derived from the amplification of the 5´adjacent region (primer pair 141up2f-2r) and 
the 3´adjacent region of the provirus (primer pair 141int3f-3r) as well as the PCR 
product derived from the allele lacking the provirus (primer pair 141exc2f-2r) are 
shown.  
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b) Positions and nature of 13 polymorphic sites in the upstream region (upper panel) 
and of 13 polymorphic sites in the downstream region (middle panel) are shown. 
Examples of polymorphic positions are indicated by electropherograms. The 
integration site of the provirus as well as the closest polymorphic positions are 
indicated in an alignment (lower panel). 
3.2.  Defining gRNAs 
The polymorphic sites in the flanking regions of the chr1:41Mb locus allowed an 
optimal design of the gRNAs for the excision of the provirus through CRISPR/Cas9 
technology. Three gRNA were designed, two upstream of the 5’ LTR and one 
downstream of the 3’ LTR. gRNA candidates were designed by Chop Chop and the 
gRNAs that presented high efficiency and specificity value were chosen for the 
excision of PERV C (Fig. 11). gRNA51 and gRNA52 are located respectively 0.717 
kb and 0.776 kb upstream of the provirus and gRNA31 is located 0.592 kb downstream 
of the provirus. Thus, successful gene editing will result in the excision of the provirus 
and approximately 1.3 kb of its flanking regions. 
 
Figure 11: gRNAs position outside PERV C and example RNAs designing by chop 
chop. 
 
 
 
 
IV. Results 64 
 
 
 
Plasmid vectors expressing the respective gRNA under the control of a human RNA 
polymerase promotor U6 were synthesized according to (MALI et al., 2013) and 
transformed in TOP 10 E.coli cells in order to verify gRNAs sequence. All 3 gRNAs 
proved to be correctly synthetized at nucleotide level (Fig. 12). 
 
Figure 12: gRNAs nucleotide sequence. For sequencing control gRNA primer (crp) 
forward and reverse were used. 
3.3.  Producing and screening 3990 single cell clones 
Transfection and production of single cell clones was performed with assistance by 
Eva Jemiller at our institute. After verification of gRNA sequences, 3990 cells were 
transfected with independent vectors encoding the Cas protein and the 3 gRNAs. 
 
 
Figure 13: Example of single cell clone at 80 % of confluence. 
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After transfection, the cells were counted, diluted and seeded into 96 well plates in 
order to have 1 cell pro well. In a first experiment, cells were seeded into a total of 10 
96 well plates. After reaching the 80 % confluence the single cell clones were splitted 
into 2 wells, one as a potential backup for somatic cell nuclear transfer and one for 
screening. In the first set of experiment 85 cell clones were obtained. After isolating 
genomic DNA from each cell clone, PCRs were performed to discriminate the allele 
with the provirus and the allele lacking the provirus (141int3f-3r,141exc2f-2r). 
Different patterns of screening products were obtained. A positive 141int3 PCR 
indicates a still abundant provirus at chr1:41Mb while a negative PCR indicates 
excision of provirus which should be accompanied by a 0.7 kb fragment in the 141exc2 
PCR. For 19 clones PCR failed; 5 clones indicated excision of the provirus and 57 
clones still retained the provirus at chr1:41Mb. If only a single 0.7 kb appeared in the 
141exc2 PCR, also the PERV C lacking allele has undergone the excision of the 1.3 
kb element between the gRNAs. If an additional 2 kb appeared, the PERV C-lacking 
allele underwent no or only minor modifications. 
 
Figure 14: Single cell clones screening PCRs. 141exc2 primer pairs amplifying the 
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entire PERV C locus and 141int3 primer pairs amplifying the transition region PERV 
C-chromosome on the 3’ end. 
 
The clones were further sequenced to verify the excision of PERV C. Three of them, 
namely 1657, 1646 and the 1681 demonstrated PERV C excision on the right allele 
and using the polymorphic sites between the allele with and without the provirus, 
further indicated that the provirus was excised by NHEJ (Fig. 15).  
 
Figure 15: PERV C locus sequencing pattern of a typical clone that lack PERV C. 
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a) The region around the 5´ cutting site is shown in an alignment and in an 
electropherogram with the adjacent SNP and the different cutting sites on the two 
alleles. On the 5’end is shown the gRNA cutting site and 2 SNPs that discriminate the 
allele with PERV C from the one that lack it. In the elctropherogram is possible to see 
the 2 SNPs peaks as well as the starting point of overlapped sequence because of a 
frameshift due to the cutting site. Overlapping sequences happened since 2 alleles are 
sequenced in the same reaction/time. b) The corresponding region for the region 
around the 3´cutting site is shown in an alignment and representative 
electropherograms. On the 3’end is shown the gRNA cutting site, 1 SNP and in 
addition a INDEL of 3 nucleotides. In the allele with PERV C there is an insertion of 
3 T in the position 1840 and this is the point where the sequence starts to overlap. 
 
Interestingly, in 2 clones (1649 and 1661) the provirus has been removed rather by HR 
than NHEJ, as indicated by the polymorphic sites (Fig. 16). 
 
 
Figure 16: PERV C locus sequencing pattern of a typical clone that lack PERV C 
not by NHEJ. No overlapped sequence is observable. 
 
 
In a second experiment 62 further cell clones were obtained and screened with the 
same primer pairs as in the first set. Of these, 12 clones lack PERV C and 2 clones 
(573 and 586) shown 2 unspecific bands in the 141int3 PCR (Fig. 17).  
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Figure 17: Single cell clones screening PCRs. Second set of single cell clones 
screened with 141exc2 primer pairs amplifying the entire PERV C locus and 141int3 
primer pairs amplifying the transition region PERV C-chromosome on the 3’ end 
 
All 14 clones were further tested to confirm the excision of the provirus with two 
different PCR. One PCR using the primer pairs 141up2f-2r amplifies the region of the 
chromosomal flanking region and the LTR on the 5’ end and the second PCR using 
envC1 primer pair amplifies any PERV C element. The clone 573 was positive for the 
2 PCRs, indicating still the presence of the provirus. The clones 571and 586 were 
negative for both PCRs, indicating that only those have actively removed the PERV C 
provirus. The clones (572, 578 and 580) were positive for 141up2 PCR and negative 
for EnvC1 PCR (Fig. 18b) indicating that only the 3´-region of the chr1:41Mb has 
been removed from the genome. In other words, these clones cannot be used for 
generating PERV-C free animals as a truncated PERV-C is still present. 
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Figure 18: PERV C screening. PCRs of the single cell clones that shown PERV C 
lack on the first screening. The primer pairs used are EnvC1 and 141up2.  
 
The remaining single cell clones (Fig. 18a) lack PERV C as no PCR product was 
obtained amplifying with 141up2 primer pair. The unexpected finding of a faint band 
with the envC1f-1r PCR in clones 500, 507, 521, 526, 531, 533 with the above 
mentioned unspecific amplification of a non-PERV-C element (see paragraph 2.3.). 
For the clones 515, 520, 527 and 529 the more intensive bands from the envC1f-1r 
PCR were further examined by sequencing; all of them, except 520 again revealed a 
Sanger sequence that corresponded rather to AF402663 than to the references of PERV 
A, B and C (Fig. 19).  
 
Figure 19: Sequencing of envC PCR products. env C sequences of 520, 515, 527 and 
529 cell clones compared to the sequence of PERV A, B and C. 
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3.4.  Perspective: SCNT approach  
Somatic Cell Nuclear Transfer is a preferred method to produce genetically modified 
pigs at our institute. Of the147 single cell clones 15 lack PERV C at chr1:41Mb 
(10,2%). These cell clones can be used to generate GTKO. hCD46. bLEA triple 
modified pigs lacking PERV C. The generation of such pigs is an ongoing approach. 
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V. Discussion 
With the increasing number of patients waiting for organ transplantations and the 
restricted number of human donors new alternative methods are needed to provide 
therapeutic options for the patients. Xenotransplantation using pigs as potential donor 
for organs, tissues and cells became a promising solution for closing the gap between 
the number of necessary allografts and the number of available donors, because of 
their organ size and physiological similarity to humans, their easy genetic 
manipulation and the high rate of reproduction (ONIONS et al., 2000; 
HRYHOROWICZ et al., 2017). Despite the enormous progress towards clinically 
applicable xenotransplantation in the recent past, questions regarding safety for the 
human recipient and the population has not yet been sufficiently clarified (COWAN 
& D'APICE, 2008; MATTIUZZO et al., 2008; NELLORE & FISHMAN, 2018). The 
removal of bacteria, fungi, protozoa and viruses from the source pig can be achieved 
with vaccines and drugs, designated pathogen-free (DPF) breeding conditions and 
early weaning (DENNER & MUELLER, 2015; EGERER et al., 2018), whereas this 
is not possible for PERV as they are stably integrated in the pig genome and are 
transmitted to the offspring according to Mendelian rules (ONIONS et al., 2000). 
Among the replication competent PERV, PERV C is the most critical subtype since it 
can recombine with PERV A, resulting in PERV A/C which are highly capable to 
infect human cells. Therefore, it will be essential to provide PERV C free donor 
animals for xenotransplantation. Different approaches were already tested to reduce 
the pathogenic potential of PERV C by producing neutralizing antibodies (KAULITZ 
et al., 2011a; WAECHTER & DENNER, 2014) or RNA interference, a strategy which 
silences the expression of a gene at the post transcriptional level. These approaches, 
however, only knockdown/reduce the expression of PERV without removing it 
physically from the porcine genome (MIYAGAWA et al., 2005; RAMSOONDAR et 
al., 2009; SEMAAN et al., 2012). In this doctoral thesis, 2 different strategies were 
tested to achieve the elimination of PERV C at the genomic level, namely selective 
breeding and gene editing by the CRISPR/Cas system. Targeted Locus Amplification 
sequencing was used to identify integration sites of PERV C in our herd which consists 
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of a mix of conventional pig breeds like German landrace, Swabian-Hall , Duroc and 
Pietrain. In 4 animals of our xenoherd with different genetically modified background 
we detected a total of 11 PERV C loci. None of these animals was PERV C free, but 
very importantly none of the 11 PERV C integrants was present in all of the animals. 
This finding is relevant for 2 reasons: First, the diversity of PERV C proviruses 
suggests that PERV C can be removed from the herd by selective breeding. Second, 
the diversity of PERV C load in the animals suggest a very recent timepoint for the 
integration of PERV C into the pig genome. This assumption is supported by the fact 
that the LTRs sequenced were identical within each provirus and differed only 
marginally between the LTRs of the proviruses integrated in the different loci. In this 
context it seems remarkable that one of the founder animals, the GTKO. hCD46 
modified 9948 descends from a US-based entity (Revivicor). The genetic origin of this 
individual is not fully clarified, but based on personal communication this pig has been 
produced by cross-breeding US-based individuals (PHELPS et al., 2003) with 
Australian pigs (LOVELAND et al., 2004). Still, the only PERV C provirus identified 
in 9948 was almost identical to the other PERV that obviously descend from the 
Munich herd. The diversity of PERV integration sites suggest that the different 
proviruses descend from the different pig breeds that comprise our hybrid breed 
mixture.  
Importantly, analyzing PERV C load or copy number at DNA level does not allow to 
say if these proviruses are biologically active and capable to infect. Therefore, it will 
be interesting to learn more about the capacity of the PERV C proviruses to infect new 
cells. Interestingly, in pig individual has been shown increase of proviral copy number 
in somatic cells compared to those in germinal cells, illustrating the general replication 
competence of PERV C. Whether these infection events are caused by PERV from the 
same individual or from exogenous viral particles remain unclear. Importantly, 
however, so far there has been no evidence documented that PERV C is nowadays still 
infecting the germ line (MOURAD et al., 2017; FIEBIG et al., 2018). 
The animal 3990 contains only one single provirus integration site and became our 
target for the excision of PERV C by gene editing. The identified provirus was 
localized at chr1:41Mb using the pig reference genome within a large intergenic 
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region. This is highly relevant because the excision of the provirus using 
CRISPR/Cas9 eliminated also 1.3 kb of the surrounding genomic region. Although not 
finally confirmed, the intergenic localization of PERV C suggests that an effect on the 
overall function of the pig genome is very unlikely. This would have been not the case 
if any of the gRNA used for excision of the provirus bind in regulatory regions or even 
within a coding sequence.  
All 11 PERV C loci were characterized using the flanking regions of the proviruses to 
localize the integration site and to use this DNA sequence for the establishment of site 
specific screening PCRs for every identified locus. A potential risk in the 
establishment of these PCRs was the possibility to amplify unspecific regions rather 
than PERV flanking elements. This cannot be excluded as PERV themselves as well 
as many of the flanking regions are repetitive elements and are present in high copy 
number in the porcine genome. To be sure and further verify the amplification 
specificity of the designed primer pairs, all PCR products were sequenced at a regular 
basis. In any case, the PCR products comprise the chromosomal flanking region and 
the LTR on the 5’ end and on the 3’ end of every provirus and thus resemble a robust 
screening tool for the 11 proviruses. As we have analyzed individuals only for the 11 
previously detected PERV C loci, it might be that there are some additional proviruses 
present in our herd. Indeed, in some animals we found a clear PERV C signal when 
using the unspecific envC PCR, albeit animals were clearly negative for any of the 11 
known proviruses. The significant number of animals that were evidently PERV C free 
when they appeared negative for the 11 PCR suggests, however, that this number is 
relatively low. Still it might be meaningful to re-analyze the xeno breeding herd at a 
later timepoint. Very surprisingly the PCR that we have initially designed as specific 
for env of PERV C resulted in a positive PCR signal in any animal, albeit at a much 
smaller intensity for some of the pigs such as 1621, 1622, 4679, 4688, 4689, 5004, 
5006, 5624, and 9781. Upon sequencing, however, the less intensive band appeared as 
a different sequence, correlating rather to the Gene Bank entries AF40266 and 
DQ996276. Albeit this type of PERV env has been designated on a new variant of 
PERV C (HECTOR et al., 2007), I do not fully agree with this interpretation. The 
translated amino acid sequence might rather resemble a new PERV subfamily in the 
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porcine genome with a not yet determined tropism, as the PCR amplifies a stretch from 
the receptor binding domain (RBD) (ARGAW et al., 2008; ARGAW & WILSON, 
2012) of the env gene. At the present time point, however, it is even unclear if the 
proposed new subfamily is even replication competent, as the respective Gene bank 
sequences do only comprise the env gene. In this context, it is of note that the quality 
of the pig reference genome is still not fully satisfactory. For the 11 identified PERV 
C integration sites the annotation of the nearest genes did not differ between the initial 
poor quality version 10.2 and the improved version 11.1. This is particularly true for 
the gene edited provirus at chr1:41Mb. The comparison of exon definition in the pig 
genome with BLAST matches of the corresponding human and bovine cDNA 
sequences further confirmed the characterization of the PERV integration sites. 
Despite there is evidence that there are some additional, not yet characterized PERV 
C proviruses in any pig breeding herd, here I further demonstrate that PERV C can be 
removed effectively from donor pigs through selective breeding. However, the 
maintenance of the PERV C free animal status is an interesting aspect, because the 
young age of PERV C in the pig genome suggests that proviruses might still be active. 
New integration can therefore not be excluded, if PERV C free animals are maintained 
in a facility together with PERV C positive pigs. At best, de novo infections might be 
prevented by maintaining PERV C free pigs in a PERV C free stable.  
As selective breeding requires time, space and economic resources the removal of 
PERV C by gene editing is a promising alternative way to generate PERV C free pigs. 
A ZFN-based approach was already used to knock out PERV from the porcine 
genome, but this attempt failed very likely due to the high copy number of PERV and 
the consequent introduction of multiple cutting sites in the genome resulting in DNA 
destabilization and high toxicity for the cells (SEMAAN et al., 2015). Recently, 2 other 
studies used the CRISPR/Cas technology instead (YANG et al., 2015; NIU et al., 
2017). The principle aim was the inactivation of any PERV in the porcine genome by 
introducing deleterious mutations in the proviral pol gene but without discriminating 
between PERV A, B and C. It is of note that in the work performed by NIU et al. the 
cell line was wild type and not a cell line derived from a genetically modified pig 
useful for xenotransplantation. In contrast, in this doctoral thesis I worked on 
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multimodified pigs of our xenoherd with proven protective effect in 
xenotransplantation of heart (LANGIN et al., 2018) or islets (KLYMIUK et al., 2012). 
In addition, the PERV-inactivating approach introduced multiple modifications at 
once which might anyways not be necessary, as most of the proviruses in the porcine 
genome appear replication defective. Again this doctoral thesis represents an 
alternative approach as it was the primary goal to remove only the most critical PERV, 
namely the subfamily C. For removing the sole PERV C at chr1:41Mb the locus was 
examined at the nucleotide level on both, the PERV containing and the PERV lacking 
alleles. These data at first allowed the proper design of gRNAs upstream and 
downstream of the integration sites of the provirus. In addition, the polymorphic sites 
facilitated the discrimination of the two alleles in the target cell line and, eventually, 
allowed the identification of the proposed DSB-repair pathway. Indeed, the clones 
1646, 1657, 1681 clearly showed to have repaired the DSB by NHEJ, whereas the 
clones 1649 and 1661 very likely have repaired the DSB by Homologous 
Recombination. This finding was not totally unexpected as the HR repair system was 
shown to be activated in pig primary cells (KLYMIUK et al., 2014). Still I would have 
expected HR-based repair to occur less frequently, in particular due to the fact that a 
9kb element has been excised by recombination between the homologous alleles. The 
cell clones entirely lacking the provirus will be used for producing multi-modified 
PERV C free pigs by SCNT and subsequent embryo transfer in a recipient sow.  
SCNT and embryo transfer are not very efficient techniques, characterized by poor 
pregnancy rates and frequent early neonatal death of the cloned piglets. Gene Editing 
might further impair the success of the cloning procedure due to the off-target effects. 
For generating new genetically modified pigs, however, SCNT still resembles a 
powerful method which is routinely used at the Institute of Molecular Animal Breeding 
and Biotechnologies (MABB). 
In total, I have shown that both, selective breeding as well as Gene Editing, are 
sufficient methods to remove the critical PERV C proviruses from donor pigs for 
xenotransplantation. This is a major step forward on the road to the desired usage of 
porcine grafts for clinical purposes.      
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VI. Summary 
Deleting PERV C infectious potential from donor pigs for xenotransplantation. 
The increasing demand for cells, tissues and organs for transplantation and the limited 
number of human donors cause the necessity to find alternative sources. The pig is the 
most suitable donor for this aim since this animal has similar physiological 
characteristics with humans and its genome can be easily modified for different 
purposes. However, concerning genetic differences between species, 
xenotransplantation faces higher hurdles in immunological and safety terms compared 
to allontransplantation. Different genetic approaches facilitate the generation of 
genetically modified donor pigs in order to overcome xenograft rejection. The latest 
progress in xenotransplantation preclinical studies suggest that its application on 
human patients is realistic in a foreseeable future. Therefore, safety concerns like 
pathogens transmission (xenozoonosis) need to be elucidated and prevented. For 
bacteria, fungi and viruses, strategies like the use of antibiotics, anti-fungal treatments, 
vaccines, antiviral drugs, Cesarean delivery or early weaning and maintenance under 
designated pathogen-free conditions (DPF) are used for their eradication from donor 
pigs. However, these strategies do not work for removing viruses that are permanently 
integrated into genome like PERVs. In clinical application of xenotransplantation it is 
highly required to use porcine material derived from PERV-C free animals. Therefore, 
in this thesis two strategies are investigated to remove PERV C infectious potential 
from donor pigs for xenotransplantation namely selective breeding and excision of 
proviruses from the genome by CRISPR/Cas technology. At first, PERV C integration 
sites were identified by TLA-Sequencing in 4 chosen animals of our xenoherd. The 
sequences were then annotated to the pig reference genome and the flanking regions 
of every PERV C locus were then used to characterize the chromosomal localization 
of proviruses. Totally 11 PERV C loci were found. None of the animals was found to 
be PERV C free and PERV C load ranged from 1 to 8. For each PERV C locus site-
specific PCRs were established to screen animals produced from our breeding herd. In 
a total of 278 examined animals, we found 36 PERV C free for the 11 tested loci. 
Interestingly, 4 of the identified proviruses have been extincted from our xenoherd 
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over time. Although selective breeding is a good way to remove PERV C from donor 
animals, it is time consuming. Alternatively, we aimed excising PERV C from the 
genome of a selected pig by gene editing. A single heterozygous provirus at chr1:41Mb 
was excised from a GTKO, hCD46, bLEA multimodified pig by CRISPR/Cas. At first 
polymorphisms were identified to discriminate the two different alleles. Two gRNAs 
on the chromosomal flanking regions of the provirus were defined for the excision of 
PERV C, one upstream of the 5’ LTR and one downstream of the 3’ LTR. Primary 
cells were then transfected with Cas9 and the two gRNAs. 147 single cell clones were 
screened for the abundance of the provirus by PCR and sequencing. 15 of them lacked 
the provirus and therefore will be used in somatic cell nuclear transfer (SCNT) to 
produce PERV C free animals. The production of PERV C free multimodified pigs by 
SCNT using the candidate clones is an ongoing approach at our Institute for Molecular 
Animal Breeding & Biotechnology (MABB). 
In conclusion the results obtained in this research work demonstrate that both, selective 
breeding and excision of PERV C by CRISPR/Cas technology are two efficient ways 
to reduce or eliminate the pathogenic potential of PERV C from multimodified pig 
donors for xenotransplantation. 
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VII. Zusammenfassung 
Eliminierung des infektiösen Potentials von PERV C aus Spenderschweinen für 
die Xenotransplantation. 
Die zunehmende Nachfrage nach Zellen, Geweben sowie Organen zur Transplantation 
und die zugleich begrenzte Anzahl von menschlichen Spendern verdeutlichen die 
Notwendigkeit alternative Quellen zu finden. Das Schwein ist dafür am besten 
geeignet, da es die dem Menschen am ähnlichsten physiologischen Merkmale aufweist 
und sein Genom ohne große Schwierigkeiten für verschiedenste Zwecke modifizierbar 
ist. Hinsichtlich der genetischen Unterschiede zwischen Spezies gibt es bei der 
Xenotransplantation höhere immunologische und sicherheitsrelevante Hürden als bei 
Allontransplantation. Verschiedene genetische Ansätze ermöglichen die Generierung 
von genetisch modifizierten Spenderschweinen, um der Abstoßung von 
Xenotransplantaten entgegenzuwirken. Die aktuellen Fortschritte und Ergebnisse in 
vorklinischen Studien zur Xenotransplantation legen nahe, dass die Anwendung an 
menschlichen Patienten in naher Zukunft realistisch ist. Aus diesem Grunde müssen 
Sicherheitsbedenken, wie Übertragung von Pathogenen (Xenozoonose) genau 
erläutert und ausgeräumt werden. Vorgehensweisen, wie die Behandlung mit 
Antibiotika, Antipilzbehandlungen, Impfstoffen, antiviralen Wirkstoffen sowie die 
Haltung unter designiert Pathogen-freien Bedienungen (designated pathogen free, 
DPF) nach Kaiserschnitt und mutterloser Aufzucht werden zur Eliminierung von 
Bakterien, Pilzen und Viren bei Spenderschweinen angewendet. Diese Methoden sind 
jedoch nicht geeignet, Viren wie PERV zu entfernen, die stabil im Genome integriert 
sind. In klinischen Studien zur Xenotranplantation ist es unbedingt notwendig, 
Material von PERV C freien Schweinen zu verwenden. Daher werden in dieser 
Doktorarbeit zwei Strategien untersucht, um das PERV C Infektionspotenzial von 
Spenderschweinen für die Xenotranplanation zu beseitigen und zwar durch selektive 
Zucht sowie die Entfernung von Proviren aus dem Genom durch die CRISPR/Cas 
Technik. Zuerst wurden PERV C Integrationsstellen durch TLA-Sequenzierung in 4 
ausgewählten Tieren aus unserer Herde identifiziert. Die Sequenzen wurden im 
Anschluss dem Referenzschwein annotiert und die flankierenden Regionen jedes 
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PERV C Lokus zur Charakterisierung der chromosomalen Positionen der Proviren 
verwendet. Insgesamt wurden 11 PERV C Loci gefunden. Keines der Tiere war PERV 
C frei und die Anzahl von Proviren reichte von 1 bis 8. Für jeden PERV C Locus 
wurden spezifische PCR´s etabliert, um die in unserer Zuchtherde produzierten Tiere 
zu testen.  Insgesamt haben wir 278 Tiere untersucht. Davon waren 36 frei für die 11 
getesteten PERV C Loci. Vier von den identifizierten Proviren wurden mittlerweile 
vollständig aus unserer Herde eliminiert. Selektive Zucht ist eine gute Möglichkeit, 
PERV C von Spendetieren zu entfernen, was allerdings sehr zeitintensiv ist. Alternativ 
beabsichtigten wir, PERV C aus dem Genome eines ausgewählten Schweines durch 
Gene Editing herauszuschneiden. Ein einzelnes heterozygotisches Provirus in 
chr1:41Mb wurde aus einem GTKO, hCD46, bLEA multimodifizierten Schwein durch 
CRISPR/Cas herausgeschnitten. Zuerst wurden Polymorphismen identifiziert, um die 
zwei unterschiedlichen Allelen zu diskriminieren. Zwei gRNAs wurden für das 
Herausschneiden des Provirus aus den flankierenden Regionen des Provirus bestimmt, 
eine oberhalb und eine unterhalb der Integrationstelle. Primäre Zellen wurden im 
Anschluss mit Cas9 und zwei gRNAs transfiziert. 147 Einzelzellklone wurden auf die 
Eliminierung des Provirus mittels PCR und Sequenzierung getestet. Fünfzehn dieser 
Zellen fehlte das Provirus und diese Zellklöne werden deshalb genutzt, um durch 
somatischen Zellkerntransfer PERV C freie Tiere zu generieren. Die Produktion von 
PERV C freien multimodifizierten Schweinen durch SCNT ist eine Routineprozedur 
an unserem Institut für Molekulare Tierzucht und Biotechnologie (MABB). 
In dieser Arbeit wurde damit demonstriert, dass beide Verfahren, Zucht und Gene 
Editing, effiziente Strategien sind, um PERV C aus multimodifizierten 
Spenderschweinen für die Xenotransplantation zu reduzieren bzw. zu eliminieren. 
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